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ABSTRACT 
 
The adipose tissue functions as the body’s main energy reservoir and plays a central 
role in maintaining whole body energy homeostasis. The ability to modulate this tissue’s 
inherent endocrine and metabolic functions has promising implications in treating disease 
associated with adipose tissue dysfunction. This work revolves around two diseases where 
adipose tissue inflammation and metabolic dysfunction drive the disease, obesity and 
cachexia. Both diseases impact a significant population of U.S. adults and substantially 
reduce patient quality of life.  
In this study, we first demonstrate the use of novel therapeutic platforms engineered 
to specifically target adipose tissue inflammation and lipid catabolism through localized 
drug delivery for the treatment of obesity. Specifically, we developed poly(lactide-co-
glycolide) scaffolds loaded with resveratrol, a small molecule with promising anti-obesity 
and anti-inflammatory properties, but one that suffers from poor bioavailability. Implant 
into the epididymal fat of lean mice indicates that resveratrol augments an anti-
inflammatory environment established by PLG scaffolds without drug. Furthermore, this 
strategy protected against inflammatory stimuli, such as mice fed a high fat diet and 
adipocytes treated with pro-inflammatory cytokines. Additionally, mice pre-treated with 
resveratrol loaded scaffolds and then fed a high fat diet gained significantly less body 
weight and adipose tissue mass compared to mice that received scaffolds without the drug. 
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Collectively, this shows that PLG scaffolds are a promising platform for the treatment of 
metabolic diseases.  
Secondly, we characterize the impact of chemotherapy treatment on adipose tissue 
remodeling as a model for cancer associated cachexia. Here we report for the first time that 
a clinically relevant bolus of doxorubicin significantly reduces animal body weight and 
induces fibrosis in subcutaneous adipose tissue in female rats.  Similar to cachexic patients, 
this response was associated with an increase in collagen 1 and a marker of activated 
fibroblasts. Finally, we indicate that the subcutaneous adipose tissue exhibited greater 
fibrosis compared to visceral adipose tissue. This work is expected to provide greater 
understanding of doxorubicin’s potential role in promoting cancer-associated cachexia and 
provide insight for the development of future strategies to sustain adipose tissue health 
during chemotherapy treatment. 
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CHAPTER 1 
BACKGROUND AND SIGNIFICANCE 
1.1 Obesity Epidemic 
 Obesity is a metabolic disease defined as excessive fat accumulation1. A patient is 
clinically considered obese when his or her body mass index (BMI), calculated as weight 
(kg) / height (m2), is greater than or equal to 30 and severely obese when his or her BMI is 
greater than or equal to 402. The Center for Disease Control and Prevention’s recent report 
states that 42.4% of U.S. adults (age 18 and older) are considered obese and 9.2% are 
considered severely obese based on the previously stated definitions2. In 2000, the 
prevalence of obesity and severe obesity in U.S. adults were 30.5% and 4.7%, respectively, 
indicating a striking increase in the percent of both populations over the last two decades2.  
Therefore, a significant portion of the U.S population deals with this disease and its 
associated diseases, as obesity is a key risk factor for several chronic and life-threatening 
diseases, including heart disease, stroke, type 2 diabetes, and cancer3. As the prevalence of 
obese patients increase, it is likely that the prevalence of these comorbidities will increase 
as well. Relevant to the current global public health crisis, obesity was determined to be a 
risk factor for more severe outcomes during the influenza A H1N1 pandemic of 2009 and 
therefore, is likely to also be a risk factor for COVID-194,5. In addition, not only does 
obesity have a negative impact on patient quality of life in terms of mobility, productivity, 
and mental state, but also has a significant economic impact as well. For example, the 
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healthcare costs of obese patients are approximately 30% higher than patients with a 
normal weight6. Furthermore, annual medical cost from treating obesity-related disorders 
in the U.S. is projected to increase by $28 billion per year by 2020 and $66 billion per year 
by 2030 due to the increase in prevalence of obesity and obesity related disorders6.  
Collectively, continued increase in obesity prevalence and the disease’s overwhelming 
health and economic burdens signify the need for continued research activities to further 
our understanding of the biological events driving the disease and to develop novel 
therapeutic platforms. 
1.2 Adipose Tissue Function  
Obesity is associated with excess accumulation of fat, or adipose tissue, which is 
the main organ involved in the progression of this disease.  This tissue functions as the 
body’s main energy reservoir and plays a central role in maintaining whole body energy 
homeostasis7. Adipocytes, the tissue’s parenchymal cell, accomplish this by storing excess 
caloric energy in the form of triglycerides in specialized lipid droplets8. As other organs in 
the body require energy, triglycerides are broken down into fatty acids, via a process called 
lipolysis, released into the blood stream and are ultimately taken up by the energy 
demanding organs9.   
Decades of research indicate a key function of adipose tissue as a storage site for 
lipids; however, in the last two decades, it has become well accepted that this tissue also 
functions as an endocrine organ10. Indeed, the adipose tissue regulates metabolism, 
immunity, reproduction, and many other processes required for homeostasis through the 
hormones, cytokines, and other factors it secretes8,11,12. For example, the adipose tissue 
modulates whole body metabolic systems through the release of adipokines from 
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adipocytes which travel to distant organs via the blood stream to promote certain responses 
critical to metabolic health. Commonly studied adipokine examples include adiponectin, 
an adipokine involved in increasing glucose uptake and lipid metabolism13, and leptin, 
which controls satiety10.  
The adipocyte is not the only endocrine acting cell in the adipose tissue. In fact, the 
adipose tissue is comprised of several other cell types, such as immune cells and 
stromovascular cells, that secrete various factors that can signal in both an endocrine and 
paracrine manner, impacting distant tissues as well as local adipocytes.  Macrophages, an 
innate immune cell, make up 5% of the total cells within the adipose tissue and is the largest 
immune cell population residing within the tissue14. Under lean conditions, adipose tissue 
resident macrophages possess an anti-inflammatory phenotype in which they produce anti-
inflammatory cytokines, lipid buffering, and promote insulin sensitivity15. In addition, 
adipose tissue macrophages also play a key role in immune surveillance and removal of 
dying cells via efferocytosis within the tissue14,16. Furthermore, macrophages and their 
secreted factors control adipocyte metabolic function, including lipolysis and 
differentiation16. For example, anti-inflammatory macrophages enhance mitochondrial 
activity in adipocytes in vitro via both direct-contact and non-contact mechanisms, 
suggesting the role of soluble factors17. Undoubtedly, adipose tissue function is 
inextricably linked to the immune cells present within it and their phenotype. The following 
section will further elaborate on the role macrophages play during obesity induced adipose 
tissue dysfunction.  
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1.3 Adipose Tissue Dysfunction During Metabolic Disease 
Looking at lipid metabolism through the eyes of a chemical engineer, one should 
imagine an energy balance, where the amount of energy taken into the system (i.e. eaten) 
should balance with the amount of energy needed by the system to function (energy 
expenditure).  In the case of chronic overnutrition, there is a higher amount of energy going 
into the body than what the body requires; therefore, this energy must be stored. Adipocytes 
store this energy in the form of lipids in specialized droplets18. Therefore, during obesity, 
lipid droplets become larger and in turn increase the size of the adipocytes, termed 
hypertrophy. However, the adipose tissue has limited storage capacity; therefore, chronic 
overnutrition can lead to an accumulation of lipid metabolites in other tissues, such as the 
liver and skeletal muscle.  
Lipid accumulation in the adipose tissue leads to local inflammation as the number 
of macrophages are significantly increased in the adipose tissue during obesity, making up 
to 40% of all adipose tissue cells in obese mice19. Environmental changes that occur in the 
adipose tissue during obesity development, such as an increase in lipid exposure and 
hypoxia, activates resident macrophages and adipocytes to secrete pro-inflammatory 
chemokines and cytokines, such as monocyte chemoattractant protein-1 (MCP-1), TNF-α, 
and IL-620.  Pro-inflammatory cytokine signaling can significantly modulate adipocyte 
metabolism. For example, TNF-α signaling leads to reduced glucose uptake, increased 
lipolysis, and potentially reduced adipocyte differentiation and lipogenesis21. Through the 
release of these soluble factors, the increase in the number of proinflammatory 
macrophages in the tissue has been suggested to contribute to local and systemic insulin 
resistance, potentially leading to a type 2 diabetic state21.  
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1.4 Current Obesity Treatment Strategies 
Current methods to mitigate this disease include lifestyle changes, pharmaceuticals, 
and bariatric surgery. Each of these strategies pose challenges that hinder their 
effectiveness. First, diet and exercise alone do not typically result in long term outcomes 
for those with severe obesity. For example, severely obese patients who participated in a  
dietary and physical activity intervention plan and group support sessions lost 
approximately 9% of their body weight within the first year; however, these participants 
gained almost half of their loss back by year four22.   
There are several FDA approved medications that are prescribed to patients to be 
taken in combination with lifestyle interventions as a weight loss regimen. Some of these 
medications work to make patients feel satiated faster, such as Lorcaserin, and others work 
to reduce the amount of fat absorbed after eating, such as Orlistat23. In fact, patients who 
supplement their lifestyle intervention regimen with FDA approved weight loss drugs lose 
3-9% more of their starting weight compared to those patients who do not24. However, the 
severe side effects associated with these drugs, including increased heart rate and diarrhea 
among several others, deters their use. Furthermore, in February 2020, the FDA requested 
to withdrawal Lorcaserin from the market due to an increase in potential cancer risk21. 
Therefore, these drugs are considered effective in achieving weight loss; however, their 
negative effects likely out ways their benefits.  
Finally, bariatric surgery, an option for the morbidly obese, is highly invasive and 
comes with high risks of post-operative or chronic complications25. For example, sleeve 
gastrectomy is a common bariatric surgery where the patient’s overall stomach size is 
reduced by 25%. One in every 5 sleeve gastrectomy patients develop gastroesophageal 
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reflux disease (GERD), which is associated with frequent and severe heartburn, vomiting, 
and difficulty swallowing, leading to maladaptive eating and possible weight gain25. If 
GERD does not improve naturally, medications are used to manage the severe symptoms26. 
Due to the ineffectiveness and inconveniences of the current obesity management 
strategies, it is quite evident that novel therapeutic strategies must be developed. These 
strategies should be minimally invasive, prevent unwanted side effects associated with 
systemically administered drugs and bariatric surgeries, and designed to also be combined 
with diet and exercise.  
1.5 Biomaterials for Tissue Engineering Applications  
Tissue engineering is a sophisticated collaboration between engineering, life 
sciences, pharmaceutical science, and material science. The primary goal of tissue 
engineers is to use a combination of biocompatible materials, drugs, and biological 
products, such as cells and proteins, to repair injured tissue or direct tissue function27. 
Generally, biomaterials developed for these applications are designed to allow for cell 
mobility and extracellular matrix deposition in order to enhance cell survival and integrate 
the material with the host tissue28.  Therefore, a common construct for tissue engineering 
applications is in the form of porous scaffolds fabricated from either biological or synthetic 
materials which can be loaded with drugs, proteins, cells, or a combination thereof to 
promote desired tissue events29. Undoubtedly, one of the most commonly used synthetic 
polymers for this application is poly(lactide-co-glycolide) (PLG), likely due to its 
biocompatibility, biodegradability, and previous FDA approval30. One example of an FDA 
approved PLG construct is Zoladex, a PLG matrix loaded with goserelin acetate that is 
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used as a prostate cancer treatment31. A central focus of this dissertation is the use of porous 
PLG scaffolds for adipose tissue engineering. 
Polymer scaffolds have been successfully utilized as platforms for adipose tissue 
engineering. For example, they have been supplemented with adipose derived stem cells, 
immune cells, and/or a host of different stimuli to generate healthy adipose tissue in vivo 
as a repair mechanism for soft tissue defects as well as to develop 3-dimensional in vitro 
models to better study adipose tissue biology and potential obesity therapeutics in the 
dish32–34. Furthermore, polymer scaffolds have extensively been used to enhance the 
survival of endocrine cell (islets) grafts upon implant into the adipose tissue28,35–37. 
However, to our knowledge, little efforts have been taken to use these devices to directly 
repair injured adipose tissue or impact its inherent metabolic or endocrine functions. 
Furthermore, little research has tested the benefit of these scaffolds as drug delivery 
vehicles to directly target the adipose tissue. We propose that polymer scaffolds could be 
a very convenient strategy to deliver promising anti-obesity drugs whose success may 
otherwise be hindered by poor bioavailability or harsh side effects. Furthermore, while 
scaffolds have been implanted into the adipose tissue previously, their effects on the 
adipose tissue immune compartment and lipid metabolism remains uncharacterized.  
1.6 Host Response to Biomaterial Implants 
A central aim for tissue engineers is to understand the immune response to 
biomaterial implants and develop strategies to mitigating or direct this response that ensues 
upon implant of foreign materials. The immune response to biomaterial implants within 
the adipose tissue remains largely uncharacterized; however, studies of subcutaneous 
biomaterial implant indicates a cascade of events that make up an acute inflammatory 
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phase, chronic inflammatory phase, and wound healing phase. Upon implant, injury 
disrupts homeostasis within the tissue and the adsorption of proteins on the surface of the 
material induces the acute inflammation phase38–40. During this phase, proinflammatory 
cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) as well as 
chemokines, such as CXCL1 and monocyte chemotactic protein 1 (MCP-1), are secreted 
to recruit neutrophils and monocytes from the blood stream and into the implant site38–40. 
If the material is not fully degraded during the acute phase, the chronic inflammation phase 
follows and is characterized by the presence of macrophages, monocytes, lymphocytes, 
such as natural killer (NK) cells, T cells, and B cells at the implant site38–40. The wound 
healing process begins with the resolution of inflammation through the increase of anti-
inflammatory cytokines, such interleukin-10 (IL-10), interleukin-4 (IL-4) and interleukin-
13 (IL-13), downregulation of inflammatory mediators, and apoptosis of immune cells38–
40. IL-4 and IL-13 stimulate macrophages to fuse together to form multinucleated giant 
cells at the biomaterial interface38–40. Furthermore, anti-inflammatory macrophages 
stimulate extracellular matrix remodeling and fibroblast activation resulting in the 
encapsulation of the material38–40. In terms of developing implantable devices to modulate 
adipose tissue function for the treatment of metabolic disease, it would be beneficial to 
limit inflammatory cytokine production upon implant while simultaneously enhancing 
anti-inflammatory cytokines that may improve adipose tissue health. This is particularly 
important since excess adipose tissue inflammation characterized by inflammatory 
immune cell infiltration and inflammatory cytokine production is associated with 
metabolic disease progression. 
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1.7 Fundamentals of PLG Drug Delivery Devices 
1.7.1 Fabrication of PLG Microparticles and Scaffolds   
PLG is an attractive polymer to use in the development of drug delivery devices 
due to its biodegradability, biocompatibility, and its easily tailored characteristics, such as 
molecular weight and lactide:glycolide ratio (composition) 41. In addition, it is easily 
fabricated into drug delivery devices42. Extensively used PLG drug delivery constructs are 
in the forms of microparticles and scaffolds41. Our work revolves around loading drugs 
into PLG microparticles via a single emulsion (oil in water) solvent evaporation process43. 
Briefly, PLG and drug of choice are dissolved in an organic solvent and then this mixture 
is emulsified using a homogenizer in the presence of an emulsifier (such as polyvinyl 
alcohol). This mixture is added to water in which the organic solvent is extracted thus 
hardening the oil droplets into particles. The particles are washed and removed via 
centrifugation and subsequent lyophilization. Certainly, one can directly inject these 
particles for various applications, but in the case of our work, we then mix these particles 
with a sacrificial porogen, salt, to form our porous drug loaded PLG scaffolds. Briefly, the 
particle salt mixture is pelleted under a ton of pressure in a die of specific dimensions and 
this pellet is then placed in a custom-made pressure vessel exposed to high-pressure CO2 
gas. In this environment, the glass transition temperature of PLG is reduced, therefore 
liquifying the polymer surrounding the salt crystals44. After a pressurization and 
depressurization sequence, the particles return to a solid state fused around the salt 
crystals44, which is leached from the scaffold after washing in deionized water leaving a 
porous drug loaded matrix. Once fabricated, scaffolds are dissolved in an organic solvent 
and measured against a standard curve using a spectrophotometer to determine initial drug 
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loading. Furthermore, drug release kinetics are determined by incubating drug loaded 
scaffolds in deionized water at 37 °C and 5% CO2 and then measuring the amount of drug 
in the scaffold after certain time frames. Several polymer properties can be modified prior 
to fabrication that will impact drug release from the scaffold. PLG degradation 
fundamentals and how polymer properties alter degradation are further discussed in the 
next section.  
1.7.2 Factors that Effect Release Kinetics   
PLG is deemed biodegradable as it degrades in water into lactic acid and glycolic 
acid via hydrolysis of its ester linkages45. Degradation highly depends on bulk erosion such 
that water penetrates the matrix and hydrolyzes the polymer into oligomers and then 
monomers41. A biphasic drug release profile is commonly observed using PLG devices 
where an initial burst of drug is followed by a stable release phase. The initial burst is due 
to drug on the surface as well as initial penetration of water that begins to decrease the 
molecular weight of the polymer, but has not hydrolyzed the polymer to the point of 
monomer production41. In the second phase, drug diffuses through the polymer layer as 
water hydrolizes the polymer into oligomers and monomers41. Polymer degradation can be 
modified by altering polymer characteristics, such as composition, molecular weight, and 
matrix size and geometry42. For example, degradation rate increases with the glycolic 
portion of the polymer composition; therefore, a 65:35 lactic acid to glycolic acid ratio 
degrades faster than a 75:25 ratio41. Furthermore, higher molecular weight polymers 
generally exhibit slower degradation rates. Lastly, the size and shape of the matrix will 
impact the surface area to volume ratio, which increases the degradation rate42.  Therefore, 
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PLG is a suitable material to achieve desired delivery kinetics of various drugs as the 
degradation kinetics can be easily altered by changing polymer properties.  
1.8 Resveratrol  
Resveratrol (trans-3,5,4’-trihydroxystilbene) is a naturally occurring polyphenol 
found in various plants, such as grape skins and peanuts, that, in plants, protects the plant 
against ultraviolet rays, pathogens, injury, and abiotic stresses46. Since the “French 
paradox” was termed, a proposal that wine consumption protected French people from 
heart disease despite their consumption of a high fat diet, resveratrol has established a 
reputation of providing health benefits47. Relevant to our overall work, this molecule has 
been extensively studied for its anti-inflammatory and anti-obesity properties48. For 
example, cultured adipocytes treated with conditioned media from resveratrol and LPS 
treated RAW 264.7 macrophages protected cells from elevated levels of TNF-α and IL-6 
and inflammation-related changes in adipokine gene expression49.  In addition, oral 
resveratrol treatment significantly reduced body weight and adipose tissue mass in high fat 
diet fed and genetically obese rodents50–53. Much research indicates that resveratrol 
enhances activity of proteins that lead to lipid mobility via lipolysis and lipid catabolism 
via fatty acid oxidation54–59. For example, resveratrol has shown to increase the expression 
of adipose triglyceride lipase (ATGL)52,54,55,60 and carnitine palmitoyl transferase 1 
(CPT1)56–58,61, the rate limiting enzymes involved in lipolysis and fatty acid oxidation, 
respectively18. Furthermore, these effects are likely a result of resveratrol activation of 
AMP kinase (AMPK)54,59.  Therefore, through its cellular actions in adipocytes and 
macrophages, resveratrol has achieved pre-clinical success as an obesity therapeutic.  
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However, resveratrol clinical trials have resulted in modest or no effects on 
metabolic parameters in obese and type 2 diabetic patients62,63. A significant shortcoming 
of resveratrol’s use as an anti-obesity drug that has hindered its clinical success is its poor 
bioavailability64. When taken orally, sulfate conjugation occurs rapidly in the intestine and 
liver, which appears to be the rate-limiting step in resveratrol’s bioavailability65. We 
propose that resveratrol’s clinical effectiveness as an anti-obesity drug could be improved 
by locally delivering the drug to the target tissue. Therefore, resveratrol is an appropriate 
candidate for delivery via PLG scaffold directly to the adipose tissue in order to bypass this 
rapid metabolism that occurs when the drug is taken orally.    
1.9 Resveratrol Loaded Polymer Scaffolds for Adipose Tissue Engineering  
A central hypothesis of this dissertation is that resveratrol loaded PLG scaffolds 
promote favorable immune and metabolic responses upon implant into adipose tissue 
compared to PLG scaffolds without a drug payload. A combination of animal and cell 
culture studies are utilized in this project to understand how scaffold-based delivery of 
resveratrol modulates the immune response to PLG scaffolds and enhances local lipid 
metabolism after implant into adipose tissue. The results from this work aims to 
demonstrate that this technology is a promising novel strategy for the treatment of obesity 
and lays the foundation for future studies using biomaterials as a strategy to direct the 
adipose tissue’s inherent endocrine and metabolic functions. 
1.9.1 Aim 1: Characterize the immune response to resveratrol loaded poly(lactide-co-
glycolide) scaffolds after implant into adipose tissue  
As biomaterial therapies are used to address adipose tissue dysfunction, the immune 
response to these systems must be established. This is especially important as the immune 
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compartment of adipose tissue can drive metabolic disease. Therefore, the first aim of this 
work to test the hypothesis that resveratrol delivery from PLG scaffolds would limit 
inflammation following implant into visceral adipose tissue compared to PLG scaffolds 
without drug.  In this aim, we established that PLG scaffolds implanted into adipose tissue 
of healthy C57BL/6 mice promote an anti-inflammatory environment characterized by low 
levels of pro-inflammatory cytokines compared to unmanipulated fat. Resveratrol delivery 
augments this anti-inflammatory environment by decreasing monocyte and lymphocyte 
numbers at the implant site and increasing expression of anti-inflammatory cytokines.  To 
investigate therapeutic relevancy, we investigated resveratrol delivery to induce an anti-
inflammatory response in proinflammatory environments such as adipocytes challenged 
with TNF-α and the fat pads of mice challenged with a high fat diet. This aim results in the 
conclusion that PLG scaffolds are a promising platform for the treatment of adipose tissue 
inflammation that drives metabolic disease as the polymer alone induces an anti-
inflammatory environment and that it can be easily engineered to deliver drugs that can 
further augment this response.  
1.9.2 Aim 2: Assess the efficacy of resveratrol loaded scaffolds to enhance adipose tissue 
lipid metabolism 
As a strategy to overcome resveratrol’s poor bioavailability, resveratrol was 
incorporated into the matrix of PLG scaffolds for direct delivery to the adipose tissue. The 
second aim of this project assessed the ability of resveratrol loaded scaffolds to enhance 
local lipid catabolism compared to scaffolds with no drug. Studies in this aim investigate 
adipocyte size and expression of proteins involved in lipid catabolism after implant in lean 
mice led to the proposal that resveratrol scaffolds decrease adipocyte size because 
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resveratrol increases lipid utilization in scaffold-infiltrating immune cells, possibly through 
elevating CPT1 levels or activity. Furthermore, mice pre-treated with resveratrol scaffolds 
and then fed a high fat diet gained significantly less total body weight and epididymal 
adipose tissue mass compared to mice that received scaffolds containing only polymer. 
Importantly, this scaffold-based strategy required a single administration compared to 
previous animal studies indicating that oral resveratrol delivery requires daily dosing. This 
work indicates that localized delivery of metabolism modulating agents to the adipose 
tissue may overcome issues with bioavailability and that the role of biomaterials should be 
further investigated as a therapeutic strategy for metabolic disease.  
1.10 Understanding Adipose Tissue Remodeling in Response to Chemotherapy 
A key goal of this dissertation is to develop drug loaded scaffolds to protect adipose 
tissue from inflammatory stimuli, such as high fat diet induced obesity. Like obesity, 
another instance where adipose tissue inflammation may promote the disease is cachexia66. 
Cachexia is a condition associated with involuntary adipose tissue atrophy resulting in 
considerable weight loss that affects 50-80% of cancer patients67 and is responsible for 
approximately 20% of cancer-related deaths68. This debilitating symptom of cancer 
progression significantly reduces patient quality of life and correlate with worsened 
prognosis68. This condition may be, in part, related to the use of chemotherapies, such as 
doxorubicin, an extensively used chemotherapeutic agent for the treatment of a wide 
variety of cancers69. Treatment with this chemotherapy is associated with toxicity of 
various organs, including heart, kidneys, and liver, in addition to other severe and 
unpleasant side effects70. Doxorubicin’s negative effect on adipose tissue function may 
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play a role in cachexia development; however, only few studies have pre-clinically 
characterized the impact of doxorubicin treatment on adipose tissue function71–73.  
Biopsies from cachexic cancer patients have presented with subcutaneous adipose 
tissue architectural remodeling, such as decreased adipocyte area, increased inflammatory 
cell infiltration, and extracellular matrix deposition, all of which have significant negative 
consequences to adipose tissue function and systemic processes controlled by this 
tissue74,75.  Studies have investigated doxorubicin’s impact on adipocyte lipid metabolism; 
however, few studies have aimed to understand doxorubicin’s role in promoting adipose 
tissue remodeling. Furthermore, there are several critical, unanswered questions that 
should be addressed regarding the role of doxorubicin administered dose, dosing schedule 
and the gender of the studied population in pre-clinical studies. Working to answer these 
questions will provide greater understanding of doxorubicin’s potential role in promoting 
cancer-associated cachexia and provide insight for the development of future strategies to 
sustain adipose tissue health during chemotherapy treatment. 
Aim 3: 1.10.1 Characterize the impact of a clinically relevant, chronic bolus of doxorubicin 
on adipose tissue remodeling in female rats 
To date, most in vivo work studying doxorubicin’s effect on adipose tissue has been 
tested in male rodents by injecting approximately 2 mg/kg multiple times over several 
weeks or once for few days71,73. However, this does not accurately model clinical dosages 
of most cancer patients, which is approximately 20 mg/kg once every 3 weeks. In addition, 
there is a significant need to study the effect in female rodents since doxorubicin is 
regularly used to treat several female cancers, such as breast and ovarian cancer. Therefore, 
the third aim of this project assessed the effect of a single, 20 mg/kg doxorubicin bolus on 
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adipose tissue inflammation 9 days after injection, a time point 6 days longer than other 
studies using this clinically relevant dose, in female rats. Body weight and fat pad weights 
were assessed at the end of the study as a measure of administered doxorubicin induced 
cachexia. Furthermore, remodeling was assessed by histological means, such as measuring 
adipocyte area and number, as well as staining for extracellular matrix. A possible 
mechanism of fibrosis was also developed. Visceral and subcutaneous adipose tissue 
depots were analyzed to determine fat pad anatomical location as a factor involved in the 
extensiveness of doxorubicin induced inflammation. This work results in a better 
understanding of how doxorubicin effects visceral and subcutaneous adipose tissue 
inflammation in female rats.  
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CHAPTER 2 
RESVERATROL DELIVERY FROM POROUS POLY(LACTIDE-CO-
GLYCOLIDE) SCAFFOLDS PROMOTES AN ANTI-INFLAMMATORY 
ENVIRONMENT WITHIN VISCERAL ADIPOSE TISSUE1  
2.1 Introduction
While the adipose tissue is a common site for biomaterial supported delivery of 
endocrine cells (i.e., islets), the field has yet to investigate biomaterial strategies to 
modulate this tissue’s inherent endocrine function28,35–37,76. Indeed, the adipose tissue 
regulates metabolism, immunity, reproduction, and many other processes required for 
homeostasis through the factors it secretes8,11,12,77. Therefore, an ability to control adipose 
secretory function is a promising avenue to treat metabolic diseases. In devising platforms 
to modulate the adipose tissue, it is important to consider that (i) biomaterial implant causes 
local changes in immune cell populations78 and (ii) adipose tissue function is inextricably 
linked to the immune cells resident within it79,80. Furthermore, excessive adipose tissue 
inflammation characterized by immune cell accumulation and inflammatory cytokine 
production is associated with metabolic disease15,81,82. Thus, from a tissue engineering 
perspective, it is important to understand how the adipose tissue immune environment 
                                                           
1 Murphy, K.P., Hendley, M.A., Isely, C., Annamalai, P., Pena, E., Gower, R.M. 2018. 
ACS Applied Materials and Interfaces. 10 (50): 43363-43374. Reprinted here with 
permission of publisher. 
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responds to biomaterial implants and develop strategies to modulate this response, if 
necessary.  
 The immune response to biomaterial implants within the adipose tissue remains 
largely uncharacterized; however, studies of subcutaneous biomaterial implant indicates 
there are three phases: acute inflammation, chronic inflammation, and wound healing78. 
During the acute inflammation phase, proinflammatory cytokines such as tumor necrosis 
factor-alpha (TNF-α) and interleukin-6 (IL-6), as well as chemokines, such as CXCL1 and 
monocyte chemotactic protein 1 (MCP-1), are secreted to recruit neutrophils and 
monocytes from the bloodstream and into the implant site40,78.  Chronic inflammation 
follows this phase and is characterized by the presence of macrophages, monocytes, 
lymphocytes, such as natural killer (NK) cells, T cells, B cells, and foreign body giant cells 
at the biomaterial interface40,78. The wound healing process begins with the resolution of 
inflammation through the increase of anti-inflammatory cytokines, such as interleukin-10 
(IL-10), interleukin-4 (IL-4), and interleukin-13 (IL-13), down regulation of inflammatory 
mediators, and apoptosis of immune cells40. In terms of developing implantable devices to 
modulate adipose tissue function, especially for treatment of metabolic diseases, it would 
be beneficial to limit inflammatory cytokine expression upon device implant while 
simultaneously enhancing anti-inflammatory cytokines that might improve adipose tissue 
health.  
 In this study, we investigated resveratrol release from porous poly(lactide-co-
glycolide) (PLG) scaffolds that integrate with the adipose tissue28. Resveratrol, a naturally 
occurring polyphenol, was selected because it protects mice and primates from diet induced 
obesity, in part, through its metabolic effects on adipose tissue50,53,83–85. In addition, 
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resveratrol decreases inflammation associated with biomaterial implant in bone, cartilage, 
and the vasculature86–91. However, scaffold-based delivery of resveratrol to modulate the 
immune response to biomaterial implant in the adipose tissue has not been investigated. 
Therefore, we performed the following studies to investigate whether resveratrol delivery 
from PLG scaffolds would limit inflammation and speed its resolution following implant 
into visceral adipose tissue. We chose to deliver resveratrol directly from the scaffold 
instead of oral delivery because resveratrol suffers from poor bioavailability and requires 
frequent large doses to address adipose tissue inflammation50,53,65,83. To investigate 
therapeutic efficacy of our strategy, we determined whether resveratrol delivery from 
scaffolds could induce an anti-inflammatory response in proinflammatory environments 
including adipocytes challenged with TNF-α and the fat pads of mice fed a high fat diet.  
2.2 Materials and Methods  
2.2.1 Particle Fabrication  
 Particles were produced by an oil-in-water emulsion-solvent evaporation 
technique. The oil phase consisted of a 3:1 mixture of dichloromethane (Sigma) and 
ethanol (Sigma) containing 6% w/w PLG (purchased from Evonik, 75:25 mole ratio lactide 
to glycolide, 0.76 dL/g) and 10 mg/mL of resveratrol (Sigma). The aqueous phase consisted 
of 1% w/v PVA (Sigma) dissolved in ultrapure water. The oil phase was homogenized with 
the aqueous phase using 1:7 volume ratio with a benchtop homogenizer. The emulsion was 
then immediately added to ultrapure water and stirred for 5 hour to allow particles to harden 
and organic solvents to evaporate. Particles were collected via centrifugation, washed with 
ultrapure water, and lyophilized.  
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2.2.2 Scaffold Fabrication 
 Scaffolds were fabricated by mixing PLG particles with 250-500 µm NaCl particles 
in a 1:30 ratio, and the mixture was then pelleted in a die. Scaffolds were gas-foamed using 
800 psi CO2 at room temperature in a pressure vessel. The salt porogen was removed by 
washing in ultrapure water. Complete salt removal was confirmed by scaffold weight and 
microscopy. Scaffolds that did not contain resveratrol were fabricated from particles 
produced using an oil phase that did not contain resveratrol or ethanol.  
2.2.3 Scanning Electron Microscopy 
 Particles or scaffolds were added to carbon adhesive tape on aluminum stubs and 
gold sputtered three times for 1 minute with a Denton Desk II vacuum sputter coater. 
Compressed air was used to ensure a monolayer of particles prior to sputtering. Images 
were taken on a TESCAN Vega3 scanning electron microscope at 10 kV.  
2.2.4 Measuring Resveratrol Loading Capacity and Encapsulation Efficiency in PLG 
particles and Scaffolds  
 Particles and scaffolds were weighed and then dissolved in a defined volume of 
DMSO (Sigma) and analyzed for absorbance at 330 nm, which is the maximum absorbance 
wavelength for these solutions as determined by a wavelength scan (Fig 2.1). PLG in the 
solution did not affect resveratrol’s absorbance spectrum (data not shown). Absorbance 
values were then compared to a nine-point standard curve allowing for the interpolation of 
the unknown resveratrol concentration in the sample. Standard curves were highly 
reproducible between experiments (Fig 2.2). Particle loading capacity (PLC) and scaffold 
loading capacity (SLC) was determined using equations 1 and 2, respectively.  
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PLC  μgmg	 = M μgM mg  
 
SLC  μgmg	 = M μgM mg  
MP−RSV and MS−RSV is the mass of resveratrol measured in particles and scaffolds, 
respectively. Mp and MS is the mass of particles and scaffold analyzed.  To investigate the 
effect of storage on resveratrol loading capacity, particles or scaffolds were analyzed for 
resveratrol at 2 and 52 weeks after fabrication.  
Resveratrol encapsulation efficiency was calculated for particles () and 
scaffolds () using eqs 3 and 4, respectively.  
  % = M !"#$ mg ∗  PLC  μ&'&	M()*+,-!. mg / ∗ 100 
 
2 % =  M mg ∗ SLC  μgmg	 M 344!+$ 536#- 37-!. mg ∗ PLC  μgmg	/ ∗ 100 
MP−Recovered is the mass of particles recovered after particle fabrication, MRSV−Emulsion is 
the mass of resveratrol added to the emulsion, and MP−Scaffold Fabrication is the mass of 
particles used in scaffold fabrication.  
2.2.5 3T3-L1 Cell Culture 
 3T3-L1 fibroblasts (ATCC) were differentiated into adipocytes following ATCC’s 
protocol, with slight modifications. Briefly, 3T3-L1 cells were seeded in 6-well plates at 
(2) 
(1) 
(3) 
(4) 
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80000 cells/well or 24-well plates at 20000 cells/well and cultured in DMEM (Corning 
Cellgro) supplemented with 10% Super Calf Serum (GemCell) and 1% Pen/Strep (Fisher). 
Forty-eight hours after confluence was reached, media was exchanged with differentiation 
media consisting of DMEM supplemented with 10% FBS (Fisher), 10 µg/mL bovine 
insulin (Sigma), 0.25 µM dexamethasone (Sigma), and 0.5 mM isobutylmethylxanthine 
(Sigma). Forty-eight hours after differentiation media was added, media was exchanged 
for DMEM supplemented with 10% FBS and 10 µg/mL bovine insulin. After another 48 
hours, media was exchanged for DMEM supplemented with 10% FBS. Cells were then 
cultured until treatment with particles or scaffolds, which occurred 9 days after exposure 
to differentiation media.  
2.2.6 Particle Treatment of 3T3-L1 Adipocytes and Oil Red O Assay 
On day 9 of differentiation, 3T3-L1 adipocytes in 6 well plates were treated with 
300 µg/mL of PLG particles, PLG+RSV particles 2 weeks after fabrication, or PLG+RSV 
52 weeks after fabrication. As a positive control, 3T3-L1 adipocytes were treated with 60 
µM resveratrol. Forty-eight hours later, cells were washed and then fixed using 10% 
formalin in PBS. Immediately before the experiment, particles were washed in 35% ethanol 
in water and then suspended in DMEM media.  
An Oil Red O assay was performed on fixed cells to visualize their lipid content. 
Cells were washed with ultrapure water followed by 60% isopropanol. Cells were then 
incubated with Oil Red O (Sigma) for 10 min at room temperature followed by four washes 
with ultrapure water to ensure removal of unbound Oil Red O. Images were taken on Nikon 
Eclipse Ci microscope with a 4x objective. To quantify the staining, Oil Red O was 
extracted from the cells by incubating them in 100% isopropanol for 10 min at room 
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temperature. Absorbance of the isopropanol solution was then measured at 500 nm using 
a spectrophotometer. Absorbance was normalized to that of untreated differentiated cells.  
2.2.7 Resveratrol In Vitro Release Assay  
 To investigate resveratrol release, scaffolds were weighed and then incubated under 
ultrapure water at 37 °C for 0.25, 1, 3, 7, or 14 days. At the end of the assay, scaffolds were 
retrieved from the incubator and stored in a desiccator until dry. Dryness was confirmed 
by scaffold weight. The amount of resveratrol remaining in the scaffold was then measured 
as described in Section 2.2.4.  
2.2.8 Animal Care and Scaffold Implant  
 All anima procedures were approved by the University of South Carolina 
Institutional Animal Care and Use Committee. Six week-old male C57BL/6 mice were 
purchased from Jackson Laboratories. Mice were allowed to acclimate for 2 weeks. Prior 
to implant, all scaffolds were washed in 70% ethanol and then rinsed in sterile PBS. Mice 
were anesthetized with isoflurane, and the surgical site was shaved and disinfected with 
betadine and alcohol. Following a lower abdominal midline incision one scaffold was 
wrapped into each epididymal fat pad (i.e., each mouse received two scaffolds). The 
abdominal wall was then closed with a running stitch and the skin was closed with wound 
clips. Epididymal fat pads were collected for analysis 3, 7, or 14 days after implant.  
2.2.9 Flow Cytometry  
 Seven and 14 days after implants, epididymal fat pads were harvested following 
euthanasia and washed in ice cold PBS (Sigma). Fat pads were minced, digested in 
collagenase (Liberase TL, Roche), and passed through a 100 µm filter. The stromal 
vascular fraction was harvested by centrifugation, washed in MACS buffer (PBS, 0.5 mM 
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EDTA, 30% BSA) and incubated with anti-CD16/32 prior to adding an antibody cocktail 
against extracellular antigens. The following antibodies were purchased from Biolegend: 
anti-CD45 clone 30-F11, anti-Ly6G clone 1A8, anti-F4/80 clone BM8, anti-NK1.1 clone 
PK136, anti-CD19 clone 6D5, anti-CD11b clone M1/70, anti-CD3 clone 17A2, and 
Trustain fcX (anti-CD16/32) clone 93. The following isotype controls were also purchased 
from Biolegend: mouse IgG2a clone MOPC-173, rat IgG2a clone RTK2758, rat IgG2b 
clone RTK4530. After antibody incubation, cells were washed, fixed, and analyzed using 
a FACS Aria flow cytometry (BD Biosciences). The number of CD45 cells in each flow 
cytometry sample was calculated using Bang’s Laboratories Flow Cytometry Absolute 
Count Standard, which was added prior to data acquisition. FlowJo software (Treestar) was 
utilized to compensate and analyze data. FMOs with isotype controls were used to 
determine specific antibody signal. The gating scheme used in the flow cytometry analysis 
is depicted in Figure 2.3. 
2.2.10 Enzyme Linked Immunosorbent Assay (ELISA)  
 Following euthanasia, epididymal fat pads were harvested at 3, 7, or 14 days after 
scaffold implant, washed in ice cold PBS, frozen on dry ice, and stored at -80°C until 
homogenization. Prior to homogenization, tissues were weighed and then homogenized in 
a defined volume of RIPA buffer containing Halt Protease Inhibitor Cocktail (Thermo 
Fisher Scientific), PhosStop (Sigma), and phenylmethylsulfonyl fluoride (PMSF) protease 
inhibitor (Thermo Fisher Scientific) using a benchtop homogenizer. Insoluble materials 
was removed by centrifugation. Whole tissue homogenate samples were aliquoted and 
stored at -80°C until use.  
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 All cytokines were measured in whole tissue homogenate using Duoset ELISA kits 
(R&D Systems); however, several modifications were made to the manufacturer’s 
instructions to improve sensitivity. A high binding 96-well plate was incubated with 
capture antibody overnight at 4°C. The plate was then blocked with 10% BSA for 3 hours 
at room temperature. Samples were incubated on the plate overnight at 4°C. Detection 
antibody incubation lasted for 3 hours at room temperature before incubation with 
streptavidin-HRP for 2 hours at room temperature. After incubation with the substrate for 
20 minutes, stop solution was added to stop the enzymatic reaction, and absorbance was 
measured at 450 nm. Background was removed by measuring absorbance at 540 nm. A 
standard curve was used to determine each cytokine concentration in each sample.  
2.2.11 Western Blotting  
 Whole tissue homogenate was obtained as stated in the previous section. Total 
protein in the sample was quantified using the Pierce BCA protein assay kit (Thermo Fisher 
Scientific). 30-50 µg of protein was separated by 8-15% SDS polyacrylamide gel 
electrophoresis, depending on targeted molecular weight, and transferred to 0.2 µm 
nitrocellulose membranes. The membranes were blocked with 5% nonfat dry milk in Tris-
buffered saline containing Tween-20 (TBST) for 1 hour at room temperature. Primary 
antibodies for Bax, Mcl-1, and IL-6 were purchased from Cell Signaling Technologies, 
CD206 was purchased from Abcam, and arginase-1 was purchased from Santa Cruz 
Biotechnology. Each primary antibody was added to each blot at 1:1000 dilution, with the 
exception was arginase-1 which was added at 1:100 dilution, in 5% nonfat dry milk in 
TBST overnight at 4°C. Each membrane was then washed with TBST before incubation 
with a polyclonal secondary antibody (Abcam) or, in the case of arginase-1, a monoclonal 
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secondary antibody (Biorad), conjugated to horseradish peroxidase for 1 hour at room 
temperature. The blots were then developed with SuperSignal enhanced chemiluminescent 
substrate solution (Pierce). To verify equal loading of samples, blots were incubated under 
stripping buffer for 20 minutes and washed with TBST. The blot then underwent the same 
protocol as previously stated to probe for GAPDH (Cell Signaling Technologies). 
ImageLabs software was used to analyze the relative intensity of each protein.  
2.2.12 High Fat Diet Feeding  
Mice were allowed to acclimate for 2 weeks prior to being placed on a 60% high 
fat diet (Research Diets D12492) while a control group was kept on a normal chow diet. 
The high fat diet was initiated 1 week prior to scaffold implant, and the mice remained on 
the diet until the end of the study. Five weeks after scaffold implantation, mice were 
sacrificed under anesthesia, and epididymal fat pads were collected for analysis. Fat pads 
were homogenized and analyzed for cytokine expression using ELISA.  
2.2.13 In Vitro Model of 3T3-L1 Adipocyte Inflammation  
 On day 9 of differentiation, PLG or PLG+RSV scaffolds were introduced into wells 
containing 3T3-L1 adipocytes. Prior to addition, all scaffolds were washed in 70% ethanol 
and then rinsed in sterile PBS. After 72 hours of pretreatment with the scaffold, 10 ng/mL 
TNF-α was then added to each well and allowed to incubate for an additional 24 hours. 
Media was collected at this time point for further analysis. Differentiated cells not treated 
with TNF-α served as a control. Cell media collected at the end of the experiment was 
analyzed for MCP-1 using a Duoset ELISA kit (R&D Systems).  
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2.2.14 Statistics 
 Comparisons between two or more groups over time were conducted with a two-
way ANOVA followed by Tukey’s multiple comparisons test. The p-values calculated by 
the two-way ANOVA which addresses the effect of resveratrol, time, and the interactions 
between the two are reported as pdrug, ptime, and pinteraction, respectively. Comparisons 
between three groups at a single time point were made with a one-way ANOVA followed 
by Tukey’s multiple comparisons test. Comparisons between two groups at a single time 
point were made with an unpaired t test. The number of samples analyzed and the statistical 
analysis performed are detailed in each figure legend. All analyses were completed using 
GraphPad Prism. In all figures, the error bars denote standard error of the mean (SEM).  
2.3 Results 
2.3.1 Characterization of Resveratrol Scaffolds  
 Resveratrol loaded PLG particles (PLG+RSV) were prepared using a single 
emulsion and solvent evaporation technique. The morphology of these particles and 
particles containing only the polymer (PLG) is shown in Figure 2.4 A-B. The images show 
that the morphology of PLG+RSV particles are irregular in shape compared to PLG 
particles, which are spherical. These particles were then used to fabricate scaffolds using a 
gas foaming and particulate leaching method. The structure of PLG+RSV and PLG 
scaffolds are shown in Figure 2.4 C-D. Both scaffolds contain a similar porous structure 
indicating that particle morphology does not have an impact on scaffold structure. During 
the gas foaming process, the polymer is saturated with high pressure CO2 (800 psi) which 
leads to the nucleation and growth of gas pores in the polymer particles44. The polymer 
particles expand and fuse around the salt particles, resulting in a continue matrix44. It is 
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likely that the gas foaming process is the reason why particle morphology does not impact 
the final scaffold structure.  
 The amount of resveratrol in particles and scaffolds was measured by dissolving 
the polymer in DMSO and measuring the absorbance of the solution at 330 nm. Resveratrol 
encapsulation within PLG particles is reproducible, with three representative batches 
containing 54±2, 61±2, and 59±1 µg resveratrol/mg particles (Figure 2.5A). Scaffold 
fabrication from these particles is also reproducible. After salt leaching, scaffolds made 
from the particles in Figure 2.5A contained 35±1, 36±3, and 36±3 µg resveratrol/mg 
scaffold (Figure 2.5B) and weighed 2.29±0.02, 2.48±0.17, and 2.43±0.07 mg (Figure 
2.5C). The amount of resveratrol in a scaffold can be calculated by multiplying the loading 
capacity by the scaffold weight, which was between 80 and 90 µg. Collectively, this data 
demonstrates we can fabricate resveratrol loaded scaffolds with reproducible drug 
payloads.  
 The drug encapsulation efficiency in the particles was 20.3 ± 0.7% (Table 2.1). This 
encapsulation efficiency was impacted by the mass of PLG particles we were able to 
recover following the single emulsion/solvent evaporation fabrication procedure. The mass 
yield for particles was typically 40%. Drug loading capacity dropped from ~60 µg/mg for 
particles to ~35 µg/mg for scaffolds, giving the scaffolds a drug encapsulation efficiency 
of 59.6 ± 3.1% (Table 1). Inspection of our fabrication procedure suggests that resveratrol 
is lost during the salt porogen removal step because scaffolds assayed immediately after 
gas foaming have a drug encapsulation efficiency of nearly 100% (data not shown).  
 Resveratrol stability, which is indicated by its absorption at 330 nm92, was studied 
by analyzing a fourth batch of particles and scaffolds shortly after fabrication and one year 
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later (Figure 2.6 A-B). When particles were analyzed immediately after fabrication, they 
contained 65 ± 0.5 µg resveratrol/mg particles and when this same batch of particles were 
analyzed one year later, they contained 61 ± 6 µg resveratrol/mg particles (Figure 2.6A). 
When scaffolds analyzed directly after fabrication, they contained 37 ± 0.6 µg 
resveratrol/mg scaffold, and when scaffolds from the same batch were analyzed one year 
later, they contained 36 ± 0.4 µg resveratrol/mg scaffold (Figure 2.6B). These results 
indicate that resveratrol activity is not lost after one year when resveratrol particles or 
scaffolds are kept in dry conditions and protected from light.  
 To confirm that resveratrol was active after one year of encapsulation in PLG, we 
investigated the ability of PLG+RSV particles to induce lipolysis in differentiated 3T3-L1 
adipocytes by measuring lipid content with an Oil Red O assay. We found that PLG+RSV 
particles stored for either 2 or 52 weeks significantly decreased lipid content of the 
adipocytes to a similar extent, while lipid content was not affected by the PLG particles 
(Figure 2.6C). Representative microscopic images were used to validate the decrease in 
lipid staining in the PLG+RSV and RSV treated groups (Figure 2.6D). Collectively, these 
results demonstrate that resveratrol remains bioactive after its encapsulation in PLG and 
that it remains active for at least one year.  
 The resveratrol release profile of scaffolds over 14 days was characterized in vitro 
(Figure 2.7A). At each time point scaffolds were removed from the assay and tested for 
resveratrol content. The initial amount of resveratrol in the scaffold was taken to be the 
average amount of resveratrol measured in three scaffolds from the same batch 
immediately after salt leaching. Resveratrol exhibited a biphasic release pattern (burst 
followed by a plateau), with ~50% of the drug released in the first 3 days. The amount of 
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resveratrol released during the plateau phase accounted for ~10% of the initial resveratrol 
in the scaffold. The release profile indicated that there was ~30% of the resveratrol present 
within the scaffold after 14 days. Importantly, this burst release of resveratrol could be 
beneficial in decreasing the acute inflammatory phase which occurs 1-5 days after injury. 
Minimal scaffold degradation (~5% mass loss) was required for drug release over this time 
period (Figure 2.7B). 
2.3.2 Effect of Resveratrol on Immune Cell Infiltration Following Scaffold Implant  
 To quantify the effect of resveratrol on immune cell infiltration into adipose tissue 
following scaffold implant, we employed flow cytometry. Total immune cell numbers were 
measured based on CD45 expression 7 and 14 days after implant (Figure 2.8A). As 
expected, PLG scaffold implant increased immune cell numbers at day 7. Contrary to our 
expectations, resveratrol did not decrease immune cell numbers at this time point relative 
to PLG scaffolds. Surprisingly, immune cell numbers significantly decreased from day 7 
to day 14 for both scaffold groups, and we could not detect differences between any of the 
groups at day 14 by Tukey’s multiple comparison’s test. The data indicate immune cell 
infiltration following PLG implant into fat largely resolves within 2 weeks without 
intervention. While not significant, immune cell numbers in the PLG+RSV group tended 
to be higher at day 7 and lower at day 14 compared to the PLG group.  
 To better understand these trends, 7 immune cell populations were measured at 7 
and 14 days: macrophages (F4/80), neutrophils (Ly6G), monocytes (CD11b), NK cells 
(NK1.1), T cells (CD3), NKT cells (NK1.1 CD3), and B cells (CD19) (Figure 2.8B-C). 
For ease of interpretation, immune cell numbers for the scaffold groups are normalized by 
the naïve controls. At day 7, resveratrol delivery resulted in a significant increase in 
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neutrophils with a concomitant decrease in T cells, NK cells, and NKT cells (Figure 2.8B). 
At 14 days, all populations exhibited a trend of decrease, but only monocytes, NK cells, 
and B cell numbers were significantly lower in resveratrol groups (Figure 2.8C). The data 
suggest that even though resveratrol dose not decrease the total number of immune cells, 
it does have an impact on particular immune cell populations.  
 Flow cytometry revealed that macrophage number was not different between PLG 
and PLG+RSV at either time point; however, we hypothesized that resveratrol may modify 
macrophage phenotype. To identify changes in macrophage phenotype, two molecules 
associated with M2 polarization, CD206 and arginase-193, were measured in scaffold 
homogenates 7 days after implant using Western blot (Figure 2.9A).At this time point, 
CD206 was unchanged in both the PLG and PLG+RSV scaffold groups compared to naïve 
fat (Figure 2.9B). In contrast, arginase-1 was ~35 fold higher in both PLG and PLG+RSV 
groups compared to naïve fat (Figure 2.9C). The data indicate that resveratrol delivery does 
not impact CD206 or arginase-1 expression, but scaffold implant elevates arginase-1 
expression above naïve levels.  
2.3.3 Effect of Resveratrol on Cytokine Levels Following Scaffold Implant  
 Cytokines control immune cell infiltration, residence, and survival in the tissue. 
Thus, we investigated the effect of resveratrol delivery on protein levels of 
proinflammatory cytokines MCP-1, TNF-α, IL-6, and CXCL1 as well as anti-inflammatory 
cytokines IL-4, IL-10, and IL-13 in whole tissue homogenates 3, 7, and 14 days after 
scaffold implant. There was no significant interaction (pinteraction) between drug treatment 
and time detected by two-way ANOVA for the analyses performed in Figure 2.10H. MCP-
1 exhibited the largest increase following PLG scaffold implant of all cytokines measured, 
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but was not affected by resveratrol (Figure 2.10A). MCP-1 expression significantly 
decreased by day 14 as determined by Tukey’s multiple comparisons test. Interestingly, 
scaffold implant, irrespective of drug payload, did not increase whole tissue levels of TNF-
α, IL-6, or CXCL1 compared to naïve levels (Figure 2.10 B-D). We did detect a significant 
effect of resveratrol on TNF-α (pdrug=0.0147) and CXCL1 (pdrug=0.0168) by two-way 
ANOVA (Figure 2.10 H), but drug delivery largely served to bring expression up toward 
naïve levels. To validate these findings, Western blot was used to detect IL-6 in all groups. 
We were not able to detect IL-6 in any tissues by this method; however, IL-6 was detected 
in Raw 264.7 cells after incubation with LPS and Brefeldin A (Figure 2.11).  
 In terms of anti-inflammatory cytokines, scaffolds, irrespective of drug payload, 
did not modulate IL-4 expression (Figure 2.10E). On the other hand, there was a significant 
effect of resveratrol on IL-10 (pdrug=0.0065) and IL-13 (pdrug=0.0023), with resveratrol 
increasing expression of both these proteins. In addition, expression of both these 
molecules increased over time (Figure 2.10F-G). Together, these results suggest that 
resveratrol’s effect on IL-10 and IL-13 may be responsible for decreases in immune cell 
numbers at day 14 as measured by flow cytometry (Figure 2.8B-C).  
2.3.4 Effect of Resveratrol on Bax and Mcl-1 Following Scaffold Implant 
 Apoptosis is increased in tissues during resolution of inflammation, reflecting the 
clearance of immune cells that are no longer needed40,94. In addition, resveratrol increases 
immune cell apoptosis, especially in neutrophils95–102. Thus, we measured the expression 
of Bax, a proapoptotic protein, and Mcl-1, an antiapoptotic protein, in whole tissue protein 
homogenates 7 and 14 days after implant (Figure 2.12A). Bax and Mcl-1 proteins were 
present in naïve fat (Figure 2.12A), but only Bax levels increased with scaffold implant 
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(Figure 2.12A); Mcl-1 levels were largely unaffected (Figure 2.12B). There was no 
significant interaction between treatment and time detected by two-way ANOVA for 
Figure 2.12B or Figure 2.12C. There was a trend for resveratrol to increase Bax levels, but 
it was not significant (pdrug=0.0508); however, over time Bax expression did decrease 
(pdrug=0.0040). Collectively, these results suggest that scaffold implant into the fat may 
increase rates of apoptosis since proapoptotic Bax increase and antiapoptotic Mcl-1 is 
relatively unchanged; however, resveratrol’s ability to alter Bax expression, if indeed it 
does, was difficult to detect.  
2.3.5 Ability of Resveratrol to Induce Anti-Inflammatory Responses in Inflammatory 
Environments  
 An important application of PLG+RSV scaffolds would be to induce an anti-
inflammatory response in inflamed adipose tissue. To investigate the ability of PLG+RSV 
scaffolds to achieve this, we utilized a common model of adipose tissue inflammation in 
which mice are fed a high fat diet. Mice received PLG or PLG+RSV scaffolds in both 
epididymal fat pads 1 week after being fed a high fat diet. The mice were then fed the diet 
for an additional 5 weeks prior to harvest of the epididymal fat (Figure 2.13A). Cytokine 
analysis was conducted using ELISA to measure MCP-1, IL-10, and IL-13 in the 
epididymal fat. High fat diet feeding resulted in an increase in proinflammatory cytokines 
MCP-1 and a decrease in anti-inflammatory cytokines IL-10 and IL-13 (Figure 2.13B). 
The results demonstrate that PLG+RSV scaffolds, but not PLG scaffolds, significantly 
decreased MCP-1 expression in the epididymal fat. Interestingly, PLG+RSV scaffolds did 
not increase the expression of IL-10 and IL-13.  
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 To investigate resveratrol’s anti-inflammatory effect on adipocytes, we utilized an 
in vitro model of adipocyte inflammation. On day 9 after differentiation, cells were treated 
with PLG scaffolds or PLG+RSV scaffolds for 72 hours and then treated with 10 ng/mL 
TNF-α for 24 hours (Figure 2.13C). Media was collected and analyzed for MCP-1 using 
ELISA. Differentiated cells that were treated with TNF-α secreted ~2.5 fold more MCP-1 
compared to untreated differentiated cells (Figure 2.13D). PLG scaffolds had no effect on 
MCP-1 secretion; however, PLG+RSV scaffolds significantly decreased MCP-1 compared 
to differentiated cells treated with only TNF-α or pretreated with PLG scaffolds prior to 
TNF-α treatment.  
2.4 Discussion  
 This report presents the characterization of resveratrol loaded PLG scaffolds and 
their novel use in modulating the immune response to biomaterial implants in the adipose 
tissue. Porous PLG scaffolds containing resveratrol were fabricated using a gas 
foaming/particulate leaching method in which NaCl served as the sacrificial porogen. To 
our knowledge, this approach is not commonly used for the fabrication of small molecule 
loaded PLG scaffolds, and our results provide further insight into drug loading and release 
kinetics of this approach. Our scaffolds contained 37 µg of resveratrol per mg of PLG 
(Figure 2.5), which is at least 4-fold higher loading than previous studies using 
biodegradable polyester scaffolds to deliver resveratrol86,91. However, this scaffold 
fabrication method was suboptimal because removal of the salt porogen led to a 40% loss 
of resveratrol loaded in the scaffold. To improve drug loading efficiency of scaffolds, a 
nonparticulate leaching method to promote scaffold porosity should be investigated. 
Nonetheless, resveratrol loaded scaffolds fabricated using this method exhibited a burst 
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and plateau release profile (Figure 2.7) and overall delivered a large amount of resveratrol 
over 14 days compared to sintered resveratrol encapsulated PLG nanoparticles which 
delivered 7 times less resveratrol in a sustained manner86. In addition, resveratrol in our 
PLG scaffolds did not degrade over one year when stored at room temperature conditions 
as determined by measuring absorbances at the wavelength of trans-resveratrol, the active 
isomer of resveratrol103. Furthermore, we confirmed this finding with a bioactivity assay 
that indicated both fresh PLG+RSV particles and those stored for one year induced 
lipolysis in 3T3-L1 adipocytes and to the same extent (Figure 2.6). The ability to maintain 
bioactivity while stored at room temperature is an advantage of small molecule delivery 
compared to other immunomodulatory strategies that require temperature-controlled 
storage. For example, proteins and viral vectors are kept at freezing temperatures to 
maintain activity, posing challenged during manufacturing, storage, and transportation 
once in the market.  
Initially, in vivo studies investigated resveratrol delivery as a way to modulate the 
immune environment within adipose tissue following implant of PLG scaffolds. 
Resveratrol impacted the prevalence of monocytes and several lymphocyte populations 
over the time course of our experiments (Figure 2.8). Monocytes and lymphocytes play 
key roles in adipose tissue inflammation during obesity104; therefore, the ability to 
modulate their number is significant to future therapies. Monocytes and lymphocytes are 
recruited to sites of inflammation by inflammatory cytokines. Resveratrol delivery 
increased expression of the anti-inflammatory cytokines IL-10 (Figure 2.10), which 
inhibits inflammatory cytokine production and signaling in many cell types, and this effect 
may be responsible for the decrease in monocytes and lymphocytes recruited to the scaffold 
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implant site. IL-10 is produced by macrophages (among other cells), with M2 polarized 
macrophages expression IL-10 at higher levels than proinflammatory macrophages105. 
Thus, we hypothesized that resveratrol delivery increased macrophage polarization toward 
an M2 phenotype within the implant site. Surprisingly, we were not able to detect elevation 
of CD206 or arginase-1, markers of M2 macrophage polarization, following resveratrol 
delivery (Figure 2.9). However, there was a 35-fold increase in arginase-1 due to the PLG 
scaffold implant and it is likely that further upregulation via resveratrol was not possible 
(Figure 2.9). In addition to IL-10, resveratrol delivery increased expression of IL-13 
(Figure 2.10), which is not produced by macrophages, but by TH2 lymphocytes, mast cells, 
basophils, eosinophils, and IL2 cells. In particular eosinophils and IL2 cells are present in 
the adipose tissue and have the ability to shape immune responses favoring immune 
resolution rather than inflammation106.  
 An ability to modulate the cytokine milieu in the adipose tissue would be useful for 
treating metabolic diseases associated with adipose tissue inflammation. Therefore, we 
investigated the efficacy of PLG+RSV scaffolds in mitigating adipose tissue inflammation 
that occurs in high fat diet fed mice. We found that resveratrol delivery decreased 
expression of MCP-1 in the adipose tissue of mice fed a high fat diet for 6 weeks (Figure 
2.13). High fat diet elevates MCP-1 after 1 week107 and promotes inflammatory 
macrophage infiltration into the adipose tissue, which drives systemic insulin resistance108. 
Therefore, decreasing this cytokine is an important benchmark for treating adipose tissue 
inflammation. We also found that pretreatment with PLG+RSV scaffolds prevented TNF-
α induced MCP-1 secretion from differentiated 3T3-L1 adipocytes (Figure 2.13), 
suggesting that the decrease in MCP-1 in vivo was mediated, at least in part, by resveratrol 
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acting on adipocytes. In contrast to healthy adipose tissue (Figure 2.9), PLG+RSV 
scaffolds did not increase IL-10 and IL-13 expression in adipose tissue from mice fed the 
high fat diet; however, scaffold implant did not further decrease the expression of these 
anti-inflammatory proteins either, which were decreased by the high fat diet. Because 
adipose tissue expression of IL-10 and IL-13 protects mice against the detrimental effects 
of high fat diet109–111, future studies should aim to quantify small molecules that increase 
these factors when released from scaffolds implanted into the adipose tissue.  
 We hypothesize that the potential mechanism for resveratrol’s protection against 
MCP-1 elevation is through its effects on the NF-κB pathway, a regulator of cytokine 
production. Resveratrol inhibits the DNA binding activity of the NF-κB complex through 
activation of Sirt-1, which inhibits NF-κB transcription in 3T3-L1 adipocytes112. 
Interestingly, upon degradation, PLG produces lactic acid, a bioactive molecule that 
abrogates the proinflammatory response of macrophages stimulated with LPS via 
downregulation of the NF-κB pathway through GPR82 receptor113,114. This is a plausible 
mechanism as to why PLG scaffold without drug loading does not produce 
proinflammatory cytokine production upon implant into adipose tissue (Figure 2.9). 
Furthermore, delivery of lactate via PLG implant accelerates the wound healing 
response115. Therefore, the delivery of resveratrol from a degrading PLG scaffold may 
synergistically promote an anti-inflammatory environment through the combinatorial 
actions of resveratrol and lactic acid on adipocytes and macrophages. Furthermore, PLG 
degradation creates an acidic environment. Resveratrol is most stable at pH < 6116,117. 
Therefore, this acidic environment could have beneficial effects on drug stability.  
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 Notable was our finding that PLG scaffold implant did not increase expression of 
TNF-α and IL-6 in the epididymal adipose tissue relative to naïve fat, and in fact, these 
cytokines appeared to decrease. Generally, the literature reports that biomaterial implant 
increases these factors and an important metric for anti-inflammatory drug delivery is the 
ability of the delivered factor to decrease their expression. However, we note from an 
extensive literature search that rarely are the experimental groups receiving the “empty” 
biomaterial and the “drug-loaded” biomaterial compared to an unmanipulated tissue37,118–
124. Thus, in these cited studies it is possible that the “drug-loaded” group actually 
decreased inflammatory gene expression below what we call “naïve” levels. On the other 
hand, we may have uncovered an attribute specific to adipose tissue. In a healthy state, the 
adipose tissue is biased toward anti-inflammation77; therefore, we hypothesize that upon 
implant the biomaterial invokes a series of signaling pathways that downregulate 
inflammatory mediators such as TNF-α and IL-6. In support of this hypothesis, we find 
that scaffold implant upregulated arginase 35-fold (Figure 2.10), an enzyme that inhibits 
production of TNF-α and IL-6125.  
 A limitation of the study is that we did not conduct a dose response. To minimize 
animal use, we chose to deliver the maximal amount of resveratrol we could in a 2.5 mg 
scaffold, which we knew from previous work is well tolerated by the mouse126. While 
resveratrol ultimately had anti-inflammatory effects, the spike in neutrophils at the 7 day 
time point that occurred with its delivery was likely counterproductive. As we believe the 
neutrophil influx was the result of local resveratrol concentrations that were too high, future 
studies should investigate not only scaffolds with lower payloads of resveratrol, but also 
scaffolds with high payloads designed to release resveratrol more slowly.  
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 In conclusion, resveratrol can be encapsulated into PLG particles using a single 
emulsion solvent evaporation technique and these particles can be formed into porous PLG 
scaffolds using gas foaming followed by particulate leaching with NaCl as the sacrificial 
porogen. This method results in scaffolds with high resveratrol loading and drug release 
with a burst phase followed by plateau. In healthy tissue, resveratrol delivery augments an 
anti-inflammatory environment established by PLG scaffolds, characterized by high 
arginase-1 and low TNF-α and IL-6, through increased expression of IL-10 and IL-13. In 
terms of therapeutic applications, PLG+RSV scaffolds decrease MCP-1 expression in the 
fat of mice fed a high fat diet, an inflammatory molecule that spurs the chronic 
inflammation associated with obesity’s comorbidities. Thus, we conclude that PLG 
scaffolds are a promising platform for the treatment of adipose tissue inflammation that 
drives metabolic disease, since the polymer alone induces an anti-inflammatory response 
and the scaffold is easily engineered for drug and cell delivery. Finally, we hypothesize 
that further investigation into the anti-inflammatory effects of PLG in the adipose tissue 
will lead to new drug targets and therapeutic strategies for metabolic disease and other 
syndromes associated with chronic inflammation.    
 
2.5 Tables 
 
 
 
Table 2.1: Resveratrol encapsulation efficiency for PLG particles and scaffolds. 
 Drug Encapsulation Efficiency (%) 
Particles 20.3 ± 0.7 
Scaffolds 59.6 ± 3.1 
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2.6 Figures  
 
 
Figure 2.1: Resveratrol wavelength scan. Wavelength scan for a solution containing 
62.5 µg/ml resveratrol dissolved in DMSO containing 1 mg/ml PLG. The black dashed 
line indicates the maximum is found at 330 nm.   
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Figure 2.2: Resveratrol PLG standard curve reproducibility. A 9 point standard 
curve for resveratrol was made using a solution of DMSO containing 1 mg/ml PLG. 
The absorbance values were measured at 330 nm and then fit on a sigmoidal curve. 
Particle and scaffold concentrations were interpolated using the standard curve. A-D 
depict standard curves made during four independent experiments.  
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Figure 2.3: Gating scheme for flow cytometry. Leukocytes were identified by CD45 
expression. Cell aggregates were removed based on forward scatter and side scatter, 
followed by side scatter width and height. For quantification of leukocytes of the 
myeloid lineage, cells positive for Ly6G (neutrophils) were first identified. Cells 
negative for Ly6G were identified and then gated for expression of F4/80 
(macrophages). Cells negative for F4/80, but positive for CD11b were gates to exclude 
expression of lymphocyte markers (CD3, NK1.1, and CD19) in order to identify 
monocytes. For the quantification of leukocytes of the lymphocyte lineage, cells were 
first based on their negative expression of  myeloid markers (Ly6G, F4/80, and CD11b). 
Cells negative for myeloid markers were then gates based on NK1.1 (natural killer cells) 
and CD3 (T cells expression. Cells positive for both NK1.1 and CD3 were identified as 
natural killer T cells. Finally, cells negative for NK1.1 and CD3 were gated based on 
CD19 (B cells) expression.  
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Figure 2.4: SEM images of resveratrol loaded PLG particles and scaffolds. (A-B) 
Scanning electron microscope images of PLG+RSV (A) and PLG (B) particles. (C-D) 
Scanning electron microscope images of scaffolds produced with PLG+RSV (C) and 
PLG (D) particles. 
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Figure 2.5: Resveratrol loading capacity of PLG particles and scaffolds.  (A) 
Resveratrol loading capacity of three representative batches of particles. Data is mean 
± SEM from three independent measurements. (B) Resveratrol loading capacity of 
scaffolds fabricated from the particles depicted in (A). Data is mean ± SEM from three 
scaffolds. (C) Mass of scaffolds depicted in (B).   
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Figure 2.6: Resveratrol loading capacity and activity after year long storage.  (A) 
Resveratrol loading capacity in a fourth batch of particles measured 2 and 52 weeks 
after fabrication. Data is mean ± SEM from three independent measurements. (B) 
Resveratrol loading capacity of scaffolds made from the particles in panel A measured 
2 and 52 weeks after fabrication. Data is mean ± SEM from three scaffolds. (C) Lipid 
content of differentiated 3T3-L1 adipocytes 48 hours after treatment with PLG particles, 
PLG+RSV particles that were 2 or 52 weeks old, or free resveratrol (60 µM). Data is 
from three independent experiments and shown as absorption normalized to 
differentiated untreated 3T3-L1 adipocytes. Statistics conducted using a one-way 
ANOVA followed by a Tukey’s multiple comparison’s test. * indicated p<0.05 
compared to PLG. (D) Representative microscopic images of Oil Red O staining.  
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Figure 2.7: Resveratrol release from PLG scaffolds. (A) Two-week in vitro release 
profile of resveratrol loaded PLG scaffolds. (B) Scaffold degradation during the release 
assay. Data is from 5 scaffolds per time point. Error bars denote SEM.   
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Figure 2.8: Effect of resveratrol on immune cell infiltration following scaffold 
implant. (A) Number of CD45 cells harvested from fat tissue following PLG and 
PLG+RSV scaffold implant measured by flow cytometry. Statistics by two-way 
ANOVA with a Tukey’s multiple comparison test. *indicates p<0.05 compared to naïve 
at day 7. † indicates p<0.05 compared to the corresponding group at day 7. (B-C) 
Immune cell numbers from tissue receiving PLG and PLG+RSV scaffolds normalized 
to naïve numbers at (B) 7 and (C) 14 days after implant. Statistics calculated using a t-
test, *indicates p<0.05 between PLG and PLG+RSV. N=8-9 scaffolds per treatment per 
time point.    
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Figure 2.9: Effect of resveratrol on expression of proteins associated with M2 
macrophage polarization. (A) Representative blot of CD206 and arginase-1 protein 
expression in adipose homogenates collected 7 days after scaffold implant. Naïve fat is 
included for references. (B-C) Quantification of (B) CD206 and (C) arginase-1 
expression from 6 mice per group. Statistics were determined using an unpaired t-test.  
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Figure 2.10: Effect of resveratrol on cytokine levels following scaffold implant. (A) 
MCP-1, (B) TNF-α, (C) IL-6, (D) CXCL1, (E) IL-4, (F) IL-10, and (G) IL-13 were 
detected by ELISA in scaffold homogenate collected 3, 7, and 14 days after scaffold 
implant. Data is from 3-4 mice per condition. (H) Table of p values determined by a 
two-way ANMOVA. * indicates p<0.05 compared to corresponding group at D7 and 
D14 determined by Tukey’s multiple comparison.  
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Figure 2.11: Detection of IL-6 in scaffold environment using western blot. (A) 
Representative western blot of IL-6 (24 kDa) expression in whole tissue homogenate 3 
days after implant. N=3 for naïve, PLG, and PLG+RSV groups. GAPDH served as 
loading control. (B) Representative western blot of IL-6 expression in RAW 264.7 cells 
after incubation with LPS and Brefeldin A (PC) and PLG homogenate 3 days after 
implant.   
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Figure 2.12: Effect of resveratrol on Bax and Mcl-1 following scaffold implant. (A) 
A representative blot of Bax and Mcl-1 protein expression in adipose homogenates 
collected 7 or 14 days after scaffold implant. Naïve fat is included for reference. (B-C) 
Quantification of (B) Bax and (C) Mcl-1 expression from 7 mice per group. (D) A table 
of the p values determined by a two-way ANOVA.  
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Figure 2.13: Ability of resveratrol to induce anti-inflammatory response in pro-
inflammatory environments. (A) Timeline of experiment for panel B. (B) MCP-1, IL-
10, and IL-13 detected by ELISA in adipose homogenate 5 weeks after scaffold implant 
in mice fed a high fat diet. Data is from 3-4 mice per group. Statistics determined by 
one-way ANOVA with a Tukey multiple comparison test. * indicates p<0.05 compared 
to HFD. (C) Timeline of experiment for panel D. (D) MCP-1 was detected by ELISA 
in media from 3T3-L1 adipocytes treated with scaffolds prior to treatment with TNF-α. 
N=4 per group. Statistics determined by one-way ANOVA with a Tukey multiple 
comparison test. * and # indicates p<0.05 compared to no scaffold and PLG, 
respectively.  
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CHAPTER 3 
MODULATION OF ADIPOCYTE SIZE AND FAT PAD WEIGHT VIA 
RESVERATROL RELEASING SCAFFOLDS IMPLANTED INTO THE 
EPIDIDYMAL ADIPOSE TISSUE2  
3.1 Introduction
The adipose tissue functions as the body’s main energy reservoir and plays a central 
role in maintaining whole body energy homeostasis77. Adipocytes, the tissue’s 
parenchymal cell, accomplish this by storing excess lipids in the form of triglycerides in 
specialized lipid droplets8. As other organs in the body require energy, triglycerides are 
broken down into fatty acids (via lipolysis), released into the bloodstream and are 
ultimately taken up by the energy demanding organ127. However, the adipose tissue has a 
limited storage capacity; therefore, chronic overnutrition can lead to an accumulation of 
lipid metabolites in other tissues128,129. Furthermore, lipid accumulation in the adipose 
tissue has significant consequences including adipose tissue inflammation and 
dysregulated insulin signaling, which are associated with metabolic diseases such as 
obesity and type 2 diabetes129,130.  
Current methods to mitigate this lipid accumulation include lifestyle changes, 
pharmaceuticals, and bariatric surgery131. Each of these strategies pose challenges that 
                                                           
2 Murphy, K.P., Hendley, M.A., Patterson, A.T., Hall, H.E., Carter, G.J., Isely, C., 
Gower, R.M. Submitted to Journal of Biomedical Materials Research Part A, 3/3/20.  
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hinder their effectiveness. Diet and exercise alone do not typically result in long term 
outcomes for those with severe obesity22 and FDA approved drugs that improve lipid 
storage in the adipose tissues, for example thiazolidinediones, are complicated by off-target 
effects including cardiotoxicity132,133. Finally, bariatric surgery is highly invasive and 
comes with high risks of post-operative or chronic complications25. Therefore, a strategy 
that enhances lipid metabolism in the adipose tissue and prevents the side effects associated 
with systemically administered drugs that can also be combined with diet and exercise 
would be highly beneficial to combat lipid accumulation.  
Biomaterials have been extensively studied to repair injured skin, bone, and muscle; 
however, only in recent years have researchers addressed adipose tissue with tissue 
engineering strategies35–37,76,134. Our recent studies indicate that, upon implant into the 
epididymal adipose tissue, scaffolds made from poly(lactide-co-glycolide) (PLG) initiate 
remodeling of the host tissue that shares many characteristics of wound healing, including 
recruitment of immune cells and extracellular matrix deposition134. This remodeling serves 
to degrade and integrate the scaffold with the host tissue. To our knowledge, no one has 
studied the metabolic consequences on the adipose tissue after biomaterial implant; 
however, we anticipate that this response is energetically demanding, and fueled, in part, 
by the metabolism of lipids135,136. In fact, our previously published results indicate that the 
host response to PLG scaffolds is responsible for enhancing local lipid utilization as 
evidenced by a decrease in epididymal fat weight in both healthy mice and mice challenged 
with a high fat diet134.  
In the current study, we investigated the hypothesis that the scaffold’s effects on 
local lipid levels could be enhanced through the incorporation of resveratrol into the 
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scaffold polymer matrix. Resveratrol, a natural polyphenol, was chosen because it 
enhances activity of proteins that lead to lipid mobility via lipolysis52,54,55,60 and lipid 
catabolism via fatty acid oxidation56–58,61. For example, resveratrol has shown to increase 
the expression of adipose triglyceride lipase (ATGL), and carnitine palmitoyltransferase 
(CPT1), the rate limiting enzymes involved in lipolysis and fatty acid oxidation, 
respectively. In addition, the literature indicates that these effects are a result of 
resveratrol’s activation of AMP kinase (AMPK)54,59. AMPK activation has shown to 
regulate ATGL expression137 and inhibit acetyl-coA-carboxylase (ACC) leading to an 
increase in CPT1 activity138.   
To study resveratrol scaffold’s effect, we first characterized the tissue remodeling 
induced by resveratrol loaded PLG scaffolds after implant into the epididymal adipose 
tissue. We hypothesized that resveratrol’s impact on metabolic programs would decrease 
lipid accumulation, as observed by adipocyte area, compared to PLG implants without a 
drug payload 28 days after implant, a time point 2 weeks longer than our previously 
published report134. Specifically, we measured resveratrol’s effect on the expression of 
ATGL and CPT1 as well as AMPK activation. Furthermore, to study the ability of 
resveratrol loaded scaffolds to prevent onset of high fat diet induced weight gain, mice 
received either PLG scaffolds without a drug payload or resveratrol loaded PLG scaffolds 
and were then challenged with a high fat diet containing 60% calories from fat, a mouse 
model of diet induced obesity139. The epididymal fat pad was chosen as the implant site 
because this fat pad expands more during the initial stages of high fat diet feeding compared 
to other fat depots140; therefore, decreasing this fat pad’s mass would be a significant 
achievement during the study time frame. While scaffolds have been used to deliver 
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resveratrol to modulate inflammation for several tissue engineering applications86–89,91,141, 
we are the first to investigate scaffold-based delivery of resveratrol to modulate metabolic 
programs in the adipose tissue.  
3.2 Materials and Methods  
3.2.1 Scaffold Fabrication  
Scaffolds were fabricated from PLG microparticles using a gas foaming, particulate 
leaching technique. Particles containing resveratrol (Sigma) were fabricated as previously 
described142. Briefly, a 1:3 volume ratio of dichloromethane (Sigma) and ethanol (Sigma) 
containing 6% w/w PLG (75:25 mol ratio lactide to glycolide 0.76 dL/g, Evonik) and 10 
mg/mL resveratrol was added to an aqueous solution of 1% w/v PVA (Sigma) in a 1:7 
volume ratio and homogenized. The emulsion was then added to ultrapure water and stirred 
for 5 hours to remove the dichloromethane and promote solidification of the polymer and 
encapsulation of resveratrol. Particles were washed with ultrapure water and collected via 
centrifugation. Particles were lyophilized and stored in aluminum foil in a desiccator to 
ensure particles were protected from light and moisture. Particles that did not contain 
resveratrol were fabricated in a similar fashion except the oil phase contained only 
dichloromethane and 6% w/w PLG.  
To fabricated scaffolds, polymer particles were mixed with a sacrificial porogen, 
NaCl (250-500 µm particles), in a 1:30 mass ratio and pelleted in a die. The resulting tablet 
was gas foamed using 800 psi CO2 at room temperature in a custom-made pressure vessel 
and the salt porogen was removed by washing in ultrapure water. Complete salt removal 
was verified by scaffold weight and microscopy. Scaffolds containing resveratrol were 
made with resveratrol loaded PLG particles and scaffolds that did not contain the drug were 
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made with particles containing only PLG. Scaffolds were fabricated so that they weighed 
2.08 mg ± 0.06 mg (mean ± SEM). From here on, scaffolds that contain resveratrol are 
referred to as “RSV scaffolds” and scaffolds containing only the polymer are referred to as 
“PLG scaffolds.” 
3.2.2 Characterizing Scaffold Structure and Pore Size  
 Scaffolds were added to carbon adhesive tape on aluminum stubs and gold 
sputtered two times for 1 minute using a Denton Desk II vacuum sputter coater. Images 
were taken on a Tescan Vega3 scanning electron microscopy at 5kV. The face of the 
scaffolds was imaged to give a top view observation. Scaffolds were also imaged using a 
Nikon Eclipse Ci microscope at 4x magnification. ImageJ was used to quantify the average 
pore diameter in both scaffold groups.  
3.2.3 Measuring Resveratrol Loading in Scaffolds  
 Resveratrol loading in scaffolds was measured as previously described142. Briefly, 
after leaching, scaffolds were weighed and dissolved in a defined volume of DMSO 
(Sigma). The solution was then analyzed for absorbance at 330 nm and absorbance values 
were compared to a nine-point standard curve allowing for the interpolation of the 
unknown resveratrol concentration in the sample. Scaffold loading was calculated as the 
amount of resveratrol measured in the scaffold (µg) normalized by the mass of the scaffold 
analyzed (mg).  
3.2.4 In Vitro Release Assay  
 Resveratrol release from scaffolds over time was determined as previously 
described. Briefly, scaffolds were weighed and incubated in ultrapure water at 37 °C for 
0.25, 1, 3, or 7 days. At each time point, scaffolds were removed from the incubator and 
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stored in a desiccator until dry, which was confirmed by scaffold weight. The amount of 
resveratrol remaining in the scaffold was measured as described in the previous section.  
3.2.5 Animal Care and Scaffold Implant  
 All animal procedures were approved by the University of South Carolina 
Institutional Animal Care and Use Committee and NIH guidelines for the care and use of 
laboratory animals were observed. Six-week-old male C57BL/6 mice were purchased from 
the Jackson Laboratory and, upon arrival, acclimated for 2 weeks prior to the scaffold 
implant procedure. Prior to implant, scaffolds were washed in 70% ethanol and rinsed in 
sterile PBS. Mice were anesthetized with isoflurane and their abdomens were shaved and 
prepped with betadine and ethanol. A lower abdominal midline incision was made, and one 
scaffold was wrapped into each epididymal fat pad (i.e. each mouse received two PLG or 
RSV scaffolds, one in each epididymal fat pad). The intraperitoneal cavity was closed with 
a running stitch and the skin was closed with wound clips.  
3.2.6 Animal Study Design  
 To investigate the effect of RSV scaffolds on adipocyte size and adipose tissue gene 
expression, three mice per group (RSV or PLG) received a scaffold into each epididymal 
fat pad and were then euthanized 28 days later. One fat pad was frozen for western blot, 
and one fat pad was fixed and embedded in paraffin for histology. In a second study 
designed to investigate adipose tissue gene expression at an earlier time point, 4 mice per 
group were implanted with one scaffold per epididymal fat pad. Fourteen-days later mice 
were euthanized and epididymal fat pads were harvested and frozen for western blot. 
To assess the effect of RSV scaffolds on mice fed a high fat diet, five mice per 
group (RSV or PLG) received a scaffold into each epididymal fat pad. Twenty-eight days 
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after scaffold implant, mice were placed on a 60% high fat diet (Research Diets D12492) 
and euthanized 28 days after induction of the diet. Fat pads were collected for protein and 
histological analysis. Mice were allowed access to the diet ad libitum during the entire 
study except when they were fasted prior to body weight measurements.  
3.2.7 Fasting Weight Measurements 
 On days 14 and 28 after initiation of the high fat diet, mice were fasted for 6 hours 
beginning at 7AM with access to water. Weight measurements were obtained by placing 
the mouse into a beaker tared on an Ohaus digital scale. 
3.2.8 Histological Analysis  
 After collection, fat pads were washed in sterile PBS, placed in 4% 
paraformaldehyde for 24 hours, and then paraffin embedded. Serial, 5 µm sections were 
cut from the paraffin blocks and stained with hematoxylin and eosin (VWR). Sections were 
imaged using a Nikon Eclipse Ci microscope at 4x or 40x magnifications. ImageJ software 
was used to quantify adipocyte area from 3 random 40x images per section. Three sections 
were quantified from 3 mice per group. All adipocytes within the field of view were 
quantified.  
3.2.8 Western Blotting  
 Collected fat pads were washed in sterile PBS, frozen on dry ice and stored at -
80°C. Tissues were homogenized in a defined volume of RIPA buffer (Fisher Scientific) 
containing Halt Protease Inhibitor Cocktail (Thermo Fisher Scientific), PhosStop (Sigma), 
and PMSF (Thermo Fisher Scientific) using a benchtop homogenizer. Insoluble material 
was removed by centrifugation and whole tissue homogenate samples were aliquoted and 
stored at -80°C until use.  
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 Total protein in the homogenate was quantified using the Pierce BCA protein assay 
kit (Thermo Fisher Scientific). Twenty or 30 µg protein was separated by 8 or 10% 
polyacrylamide gel electrophoresis based on target protein molecular weight. Separated 
proteins were then transferred to 0.2 µm nitrocellulose membranes. The membranes were 
blocked with 5% nonfat dry milk in Tris-buffered saline containing Tween-20 (TBST) for 
1 hour at room temperature. Primary antibody for phosphorylated AMPK-T172 (Cell 
Signaling Technologies, CST), ATGL (CST), phosphorylated ACC-S79 (CST), and CPT1 
(Abcam) was added to each blot at 1:1000 dilution in 5% BSA in TBST and allowed to 
incubate overnight at 4°C before incubation with a polyclonal secondary antibody 
conjugated to horseradish peroxidase (Abcam) for 1 hour at room temperature. The blots 
were then developed with SuperSignal enhanced chemiluminescent substrate solution 
(Thermo Fisher Scientific). To verify equal loading, blots were incubated with stripping 
buffer for 25 minutes and washed with TBST. The blot then underwent the same protocol 
as previously stated for total AMPK, total ACC, or GAPDH (all purchased from CST). 
Blots probed for AMPK were stripped a second time and underwent the same protocol to 
probe for GAPDH. ImageLabs software was used to analyze the relative intensity of each 
protein.  
3.2.9 Immunohistochemical Staining 
 Serial tissue sections from each mouse, 5 µm in thickness, were deparaffinized, 
rehydrated, and processed for antigen retrieval in citrate buffer using a vegetable steamer. 
Sections were blocked with a TBS solution containing Tween-20, BSA, goat serum, and 
anti-CD16/32 (Biolegend) and incubated with an anti-CPT1 antibody (Abcam). Sections 
were treated with hydrogen peroxide prior to incubation with an HRP labelled polymer 
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conjugated to goat anti-rabbit immunoglobulins (EnVision+, Dako). HRP was detected 
using the Liquid DAB+ Substrate Chromogen system (Dako). Mayer's hematoxylin (Dako) 
was used to counterstain. Three sections from each mouse were stained and then imaged 
using a Nikon Eclipse Ci microscope.  Analysis included 3 mice per group.  
3.2.10 Raw 264.7 Cell Culture and Resveratrol Treatment  
 Raw 264.7 macrophages (ATCC) were cultured at 37°C with 5% CO2 in DMEM 
media (Fisher Scientific) supplemented with 1 mM sodium pyruvate (Fisher Scientific), 
1500 mg/L sodium bicarbonate (VWR), 10% fetal bovine serum (Fisher Scientific), and 
1% penicillin/streptomycin (Fisher Scientific) at 57,000 cells/cm2 in 6 well plates. Twenty-
four hours after seeding, cells were treated with 0, 10 or 25 µM resveratrol dissolved in 
ethanol. Twenty-four hours later, cells were removed via trypsin 0.25% EDTA (Fisher 
Scientific) and a cell scraper. Cells were lysed in RIPA buffer supplemented with protease 
inhibitors via 21G needle and syringe. Protein fraction was collected after centrifugation 
at 10,000 xg for 10 minutes and stored in -20 °C. Western blot analysis of CPT1 in treated 
macrophages was conducted as previously stated using 10 µg of total protein content which 
was determined via BCA assay and β-actin (Sigma) served as the loading control.  
3.2.11 Statistical Analysis 
 Statistically significant differences between PLG and RSV implanted groups were 
evaluated using an unpaired student’s t-test. Statistically significant differences between 
three groups were determined using a one-way ANOVA with a Tukey’s multiple 
comparison test. Statistical significance was set to a p value less than 0.05. The number of 
samples analyzed is detailed in each figure legend. All analyses were completed using 
GraphPad Prism. In all figures, data indicates mean ± standard error of the mean (SEM).  
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3.3 Results 
3.3.1 Resveratrol Scaffold Characterization  
 Scaffold structure was observed using scanning electron microscopy and light 
microscopy and these images, shown in Figure 3.1 A-D, indicate that both scaffolds 
contained similar porous structure. Indeed, ImageJ analysis of light microscopy images, as 
representatively shown in Figure 1 B and D, determined the average pore diameter was 
454±31.8 µm and 434±7.45 µm in PLG and RSV scaffolds, respectively, and therefore, 
were not significantly different (Figure 3.1E). Resveratrol scaffolds used in this study 
contained approximately 48±2 µg RSV/mg scaffold; therefore, delivering approximately 
100 µg resveratrol total per 5mm x 2mm scaffold (Figure 3.1F-G). Release kinetics of 
resveratrol from scaffolds used in this study is depicted in Figure 3.2. One-week in vitro 
release characterization indicates a burst release profile where approximately 50% of the 
resveratrol initially loaded in the scaffold is released in the first 3 days with approximately 
30% of the initial resveratrol remaining in the scaffold after 7 days.  
3.3.2 Adipose Tissue Composition after Scaffold Implant  
Tissue sections from epididymal fat 28 days after PLG or RSV scaffold implant 
revealed extensive cellular infiltration and protein deposition not present in unmanipulated 
fat (Figure 3.3A,D, unmanipulated fat not shown). This tissue remodeling was localized 
around irregular shape voids indicating pieces of scaffold removed during histological 
processing (Figure 3.3 B,E; specific areas highlighted by black boxes in Figure 3.3 A,D). 
There were no obvious qualitative differences in tissue remodeling as indicated by H&E 
staining. Interestingly, however, from a metabolic perspective, adipocytes surrounding 
RSV scaffolds looked to be smaller in area compared to those surrounding PLG scaffolds 
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(Figure 3.3 C,F; specific areas highlighted by black boxes in Figure 3.3 A,D). Indeed, 
quantification of all adipocytes surrounding RSV scaffolds were approximately 1000 µm2 
compared to those surrounding PLG scaffolds which measured approximately 1500 µm2 
(Figure 3.3G). Taken together, scaffolds induce local tissue remodeling in the adipose 
tissue, while resveratrol delivery from scaffolds decreases adipocyte area compared to 
scaffolds with no drug payload.  
3.3.3 Expression of Key Proteins Involved in Lipid Metabolism Following Scaffold Implant  
 To further investigate a possible mechanism for resveratrol’s significant impact on 
adipocyte area, proteins involved in lipid regulation were measured via western blot in 
whole tissue homogenate. Adipose triglyceride lipase (ATGL), carnitine 
palmitoyltransferase 1 (CPT1), phosphorylated acetyl-co-A-carboxylase (pACC), and 
phosphorylated AMP kinase (pAMPK) levels were quantified (Figure 3.4). Interestingly, 
we did not observe a significant difference in the expression of these proteins between 
scaffold groups at the 28-day timepoint. In addition, a large amount of variability was 
observed when pACC and ACC were measured. We then looked at protein expression 14 
days after implant to determine if any differences were present at an earlier time point. 
Interestingly, at 14 days after scaffold implant, phosphorylated AMPK levels were 
significantly higher in the RSV scaffold group compared to PLG (Figure 3.5E).  
 Since CPT1 is the rate limiting enzyme involved in fatty acid oxidation, we were 
interested in how its spatial distribution was altered after RSV scaffold implant; therefore, 
we stained fat pads collected 28 days after implant with CPT1 using immunohistochemistry 
(Figure 6). We found that CPT1 was most highly expressed in the new tissue surrounding 
both scaffolds (Figure 3.6A,B). Looking more closely at the scaffold environment 
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indicated by black boxes, there is evidence indicating that CPT1 is expressed by the giant 
cells, which are formed following macrophage fusion143, located at the interface of the 
tissue and material (highlighted by yellow arrows), as well as other non-adipocyte cells in 
the new tissue (highlighted by red arrows) (Figure 3.6C,D).  
3.3.4 Expression of CPT1 in Resveratrol Treated RAW 264.7 Macrophages  
The histology presented above indicated that macrophages in the scaffold 
environment are CPT1 positive; however, we did not detect an effect of resveratrol on 
CPT1 expression using westerns, which was surprising. It is possible that carrying out the 
measurements in whole tissue homogenates kept us from detecting changes that were 
occurring in the scaffold recruited cells. To determine if it is possible for resveratrol to 
modulate CPT1 levels in macrophages, we treated RAW 264.7 macrophages with 
resveratrol and measured CPT1 protein levels via western blot (Figure 3.7A,B). Twenty-
four hours after initial seeding, the macrophages were treated with 10 or 25 µM resveratrol 
for 24 hours. Western blot indicated that 25 µM resveratrol increased CPT1 expression by 
30% relative to vehicle control (Figure 3.7B). No difference was detected between cells 
treated with 10 µM and untreated cells indicating the importance of dose.  
3.3.5 Protective Effect of Resveratrol Scaffolds in Mice Challenged with a High Fat Diet  
To determine if resveratrol loaded scaffolds could prevent diet induced obesity 
compared to PLG scaffolds, lean mice were pre-treated with RSV scaffolds for 4 weeks 
prior to being placed on a high fat diet for an additional 4 weeks, as illustrated in Figure 
3.8A. Body weight measurements indicate that 14 days after switching to the high fat diet, 
mice that received RSV scaffolds gained significantly less weight than mice that received 
PLG scaffolds (Figure 3.8B). This effect remained after 28 days on the high fat diet (Figure 
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3.8B). Additionally, at the end of the study, epididymal fat pads collected from mice that 
received RSV scaffolds weighed significantly less than those from the PLG scaffold group 
(Figure 3.8C).  
Histological sections of the epididymal fat pad collected at the end of this study 
were analyzed similarly to those in the previously discussed in the lean animal study. 
Adipocytes in the RSV scaffold group appeared smaller than those from the PLG scaffold 
group (Figure 3.9A) and, indeed, image analysis supported this observation. In fact, 
adipocyte area in the RSV scaffold group was 30% smaller compared to the PLG group 
(Figure 3.9B). Similar to results observed in the lean animal study, this observation was 
not accompanied by whole tissue modifications in ATGL, CPT1, pACC, or pAMPK in the 
RSV scaffold group (Figure 3.10).  
3.4 Discussion  
Chronic overnutrition leads to lipid accumulation that has detrimental 
consequences such as adipose tissue inflammation and dysregulated insulin signaling 
resulting in the progression of metabolic diseases such as obesity and type 2 diabetes129. 
Therefore, we are pursuing an approach to combat metabolic disease by enhancing lipid 
catabolism in the adipose tissue144. Extensive research shows that resveratrol has the ability 
to increase lipid catabolism; however, the molecule’s poor bioavailability proved to be a 
great obstacle during clinical trials64,145. As a strategy to overcome this shortcoming, we 
incorporated resveratrol into a scaffold for direct delivery to the adipose tissue and 
investigated its ability to modulate fat pad size. Mice pre-treated with resveratrol scaffolds 
and then fed a high fat diet gained significantly less total body weight and epididymal 
adipose tissue mass compared to mice that received scaffolds containing only polymer. The 
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effect on total body weight of this localized therapy might not be surprising because the 
epididymal fat pad is large, expands quickly, and contributes significantly to total body 
weight gain in this model140. Importantly, this scaffold-based strategy required a single 
administration compared to previous studies indicating that oral resveratrol delivery 
requires daily dosing50,52,61. Furthermore, it is possible that this scaffold-based strategy 
could be easily combined with lifestyle interventions, such as calorie restriction and 
physical activity, which could further enhance its potential as a promising therapy for 
metabolic diseases. 
 In both lean and high fat diet fed mice, resveratrol scaffolds reduced adipocyte area 
compared to PLG scaffolds indicating a reduction in lipid content since adipocyte area and 
lipid content are positively correlated146.  We propose that resveratrol scaffolds promote 
the utilization of lipids within the implant site and that this effect is likely due to the 
combination of the host response to biomaterial implant and the release of resveratrol from 
the scaffold. The host response exhibited here, characterized by local cellular infiltration 
and protein deposition, is similar to wound healing which depends on cellular activity that 
is largely fueled by fatty acid metabolism147–149. Furthermore, oral delivery of resveratrol 
to animals as well as treatment of cultured cells impacts the activity of several proteins 
involved in lipid metabolism, as described in several review articles58,150,151. For example, 
treatment of cultured 3T3-L1, porcine, and human adipocytes with resveratrol led to an 
increase in lipolysis as a result of elevated ATGL levels52,54,55,60,152. In addition, resveratrol 
increased CPT1 mRNA levels in adipose tissue from pigs and rats fed a resveratrol 
supplemented diet and cultured adipocytes treated with resveratrol56–58,61,51. Contrary to 
our initial hypothesis, scaffold-based resveratrol delivery did not significantly increase 
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expression of either ATGL or CPT1 when measured in whole tissue homogenate collected 
14 or 28 days after implant. We must consider that measuring these proteins in whole tissue 
may have decreased our sensitivity to see significant changes. For example, CPT1 is found 
on the mitochondrial membrane; therefore, it may be difficult to measure with high 
sensitivity in whole tissue homogenate. It is also possible we did not see differences in 
these proteins between scaffold groups at day 28 because the resveratrol payload was 
exhausted at that time point. However, we did see increased levels of activated AMPK at 
day 14 in the tissue. Literature indicates that resveratrol activates AMPK and resveratrol’s 
effect on ATGL and CPT1 are consequences of AMPK activation54,59. Thus, it is possible 
that the decreased adipocyte size at day 28 was due to increase in ATGL and CPT1 enzyme 
activity at earlier time points.  
 Remarkably, resveratrol scaffolds protected mice from high fat died induced weight 
gain and epididymal fat accumulation 8 weeks after initial implant, while the in vitro 
release profile indicates that approximately 70% of the initial resveratrol is released from 
the scaffold in the first week. We speculate that as pieces of the scaffold are encapsulated 
by the immune system, resveratrol release is slowed, extending its resident time in the 
tissue. These potential areas of high resveratrol concentration would more readily impact 
cells that are in direct contact. Therefore, we believe that macrophages are a particularly 
interesting population for further study as they are recruited to the implant site142 and fuse 
together to form multinucleated giant cells that are in direct contact with the scaffold143. 
Interestingly, we show that CPT1 is more highly expressed in the newly formed tissue 
surrounding the scaffold compared to surrounding adipocytes, and the giant cells were 
CPT1 positive.  This data is further supported by work that demonstrated that CPT1 is more 
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highly expressed in adipose tissue macrophages compared to adipocytes153. However, 
spatial information of CPT1 expression was similar in both resveratrol and PLG scaffolds; 
therefore, to further study resveratrol’s potential effect on macrophages, we treated RAW 
264.7 macrophages with resveratrol. We found that resveratrol treatment increased CPT1 
expression. It has been shown that resveratrol decreases lipid levels in RAW 264.7 
macrophages154. Our work suggests that resveratrol decreases lipid levels in RAW 264.7 
macrophages through increasing CPT1. In conclusion, we hypothesize that the mechanism 
by which resveratrol scaffolds decrease fat pad size relative to blank scaffolds is that upon 
scaffold implant, cells are recruited to the implant site, including macrophages, which can 
fuse into giant cells, and the resveratrol released increases fatty acid utilization in these 
cells leading to decreased adipocyte lipid content reflected in decreased adipocyte size. 
While this work demonstrates that resveratrol releasing scaffolds decrease fat pad 
size in mice fed a high fat diet compared to scaffolds with no drug, this study does have 
limitations. First, we focused on demonstrating a protective effect, which lays a promising 
foundation for the technology, but is not translatable to humans as this strategy will likely 
be used as an obesity intervention, not a prophylactic. Secondly, we limited the scope of 
the study to RSV scaffold’s impact on the epididymal fat pad. Due to differences in 
composition and metabolic activity in visceral and subcutaneous fat depots, it remains 
unclear if this scaffold-based strategy would achieve similar results in other fat depots. 
Furthermore, there is a question of if this strategy would need to target multiple fat depots 
simultaneously to observe a significant therapeutic effect in humans. In addition, this study 
does not address if the use of scaffolds to enhance lipid metabolism would work in other 
metabolically relevant tissues, such as skeletal muscle; however, this is the focus of future 
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work. Finally, we must consider that the extensive remodeling that occurred as a result of 
the implant may have negative effects on adipose tissue. Future work is focused on 
developing injectable technologies that would not induce extensive remodeling but would 
rather individually target immune cells to modulate gene programs involved in lipid 
catabolism. 
In conclusion, implant of resveratrol releasing scaffolds into epididymal fat of lean 
mice decreased adipocyte size, a surrogate for lipid content, compared to PLG scaffolds 
without a drug payload. Interestingly, the expression of CPT1 and ATGL, key proteins 
involved in fatty acid catabolism, whose elevated expression is associated with decreased 
adipocyte size, were unchanged in the epididymal fat at 14 or 28 days after scaffold 
implant. However, AMPK activation was increased at 14 days, which indicates that ATGL 
and CPT1 activity levels could have been elevated, providing a plausible explanation for 
the decreased adipocyte size. Histology indicated that scaffold-recruited immune cells 
expressed CPT1 at higher levels than other cells in the fat pad and resveratrol increased 
CPT1 in cultured macrophages by 30%. Thus, it is possible that our study of whole tissue 
homogenates limited our ability to detect increases in CPT1 because it was occurring in a 
small population of cells. Taken together, we hypothesize that increases in CPT1 levels 
and/or activity in macrophages within the scaffold play a role in resveratrol’s effect on 
adipocyte size. We also demonstrate that mice implanted with RSV scaffolds are more 
resistant to fat gain during 4 weeks of high fat diet compared to mice that received scaffolds 
with no drug. We also demonstrate that mice implanted with resveratrol scaffolds are more 
resistant to fat gain during 4 weeks of high fat diet compared to mice that received scaffolds 
with no drug. Importantly, this effect was realized with a single administration of scaffolds, 
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which is considerably less than the daily dosing regimen usually required for resveratrol’s 
weight loss effects on animals fed a high fat diet. We conclude that direct delivery of 
resveratrol to the fat tissue overcomes issues with bioavailability and that tissue 
engineering scaffolds can be used to achieve this goal. This work motivates further study 
into the use of biomaterials for localized delivery of metabolism modulating agents to key 
metabolic cells in adipose tissue as a treatment for metabolic disease secondary to over-
expanded adipose tissue.  
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3.5 Figures  
 
 
Figure 3.1: Scaffold characterization. (A-D) Scanning electron microscopy and 
bright field microscopy images of PLG (A-B) and RSV (C-D) scaffolds. Scale bar 
represents 500 µm for B and D. (E) Quantification of pore diameter using ImageJ 
analysis of images depicted in B and D. Data was collected from three scaffolds per 
group. Statistics were determined using an unpaired t-test. (F-G) Top (F) and side (G) 
profile of scaffold implants measuring approximately 5 mm in diameter and 2 mm in 
height.  
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Figure 3.2: Resveratrol release profile. One-week in vitro release profile of 
resveratrol loaded PLG scaffolds. Data are from 3-8 scaffolds per time point. Error bars 
denote SEM. 
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Figure 3.3: Epididymal adipose tissue remodeling after resveratrol scaffold 
implant. (A-F) Histological sections of epididymal fat pads 28 days after implant of 
PLG (A-C) or RSV (D-F) scaffolds at 4x (A,D) or 40x (B,C,E,F) magnification. Scale 
bar represents 500 µm for A and D and 50 µm for B, C, E, and F. (G) Quantification of 
adipocyte area. Data was collected from 3 40x images per section, with 3 sections per 
mouse and 3 mice per group. Statistics were calculated by an unpaired t-test. * p<0.05  
compared to PLG.  
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Figure 3.4: Effects of resveratrol scaffolds on key lipolysis and fatty acid oxidation 
protein expression 28 days after implant in lean mice. (A) Representative western 
blots of ATGL, CPT1, phosphorylated ACC (Ser79), total ACC, phosphorylated AMPK 
(Thr172), and total AMPK protein expression in adipose homogenates 28 days after 
implant. (B-E) Quantification of (B) ATGL, (C) CPT1, (D) ACC, and (E) AMPK 
expression. Data is from 3 mice per group. Statistics were calculated using an unpaired 
t-test.   
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Figure 3.5: Effects of resveratrol scaffolds on key lipolysis and fatty acid oxidation 
protein expression 14 days after implant in lean mice. (A) Representative western 
blots of ATGL, CPT1, phosphorylated ACC (Ser79), total ACC, phosphorylated AMPK 
(Thr172), and total AMPK protein expression in adipose homogenates 14 days after 
implant. (B-E) Quantification of (B) ATGL, (C) CPT1, (D) ACC, and (E) AMPK 
expression. Data is from 4 mice per group. Statistics were calculated using an unpaired 
t-test.  * indicates p<0.05 compared to PLG.  
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Figure 3.6: Spatial analysis of CPT1 in the epididymal fat pad after scaffold 
implant. (A-D) CPT1 stained histological sections of epididymal fat pads 28 days after 
implant of PLG (A,C) or RSV (B,D) scaffolds at 4x (A,B) or 40x (C,D) magnification. 
Scale bar represents 500 µm for A-B and 50 µm for C-D. Data is representative of 3 
sections per mouse with 3 mice per group.  
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Figure 3.7: Effect of resveratrol on CPT1 expression in RAW 264.7 macrophages. 
Representative western blot of CPT1 protein expression in RAW 264.7 macrophages 
treated with 0, 10, or 25 µM RSV for 24 hours. (B) Quantification of CPT1 expression. 
Data is from three 6 well plates with 2 wells per group on each plate. Statistics were 
calculated using a one-way ANOVA with a Tukey’s multiple comparison test. 
*indicated p<0.05 compared to untreated (0 µM).   
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Figure 3.8: Impact of scaffolds on weight gain and epididymal fat pad mass in mice 
challenged with a high fat diet. (A) Timeline of experiment. (B) Percent increase in 
fasting body weight relative to day 0 when the high fat diet began. (C) Epididymal fat 
pad weight 28 days after high fat diet challenge. N=5 mice per group. Statistics were 
conducted using an unpaired t-test. *indicates p<0.05 compared to PLG.  
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Figure 3.9: Effects of resveratrol scaffolds on epididymal fat adipocyte size after 
high fat diet challenge. (A-B) Histological sections of epididymal fat pads that received 
(A) PLG or (B) RSV scaffolds 28 days after high fat diet challenge taken at 40x 
magnification. Scale bar represents 50 µm. (C) Quantification of adipocyte area. Data 
collected from3 images per section, with 3 sections per mouse and 3 mice per group. 
Statistics were calculated using an unpaired t-test. *indicates p<0.05 compared to PLG.  
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Figure 3.10: Effects of resveratrol scaffolds on key lipolysis and fatty acid oxidation 
protein expression after high fat diet challenge. (A) Representative western blots of 
ATGL, CPT1, phosphorylated ACC (Ser79), total ACC, phosphorylated AMPK 
(Thr172), and total AMPK protein expression in adipose homogenates after high fat diet 
challenge. (B-E) Quantification of (B) ATGL, (C) CPT1, (D) ACC, and (E) AMPK 
expression. Data is from 5 mice per group. Statistics were calculated using an unpaired 
t-test.  * indicates p<0.05 compared to PLG.  
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CHAPTER 4 
SINGLE BOLUS DOXORUBICIN ADMINISTRATION INDUCES 
FIBROSIS IN SUBCUTANEOUS ADIPOSE TISSUE: A THERAPEUTIC 
OPPORTUNITY3 
4.1 Introduction
 Cachexia is a condition associated with involuntary skeletal muscle and adipose 
tissue atrophy resulting in weight loss that affects 50-80% of cancer patients and is 
responsible for approximately 20% of cancer-related deaths67,68. This debilitating symptom 
of cancer progression significantly reduces patient quality of life and correlates with 
worsened prognosis68. Patients that receive cytotoxic chemotherapy treatments often 
present with changes in body mass and composition155. Additionally, ovarian cancer 
patients have a worse survival rate when they lose skeletal muscle and adipose tissue mass 
while undergoing chemotherapy treatment156. Therefore, this condition may be, in part, 
related to the use of chemotherapies, such as doxorubicin. Doxorubicin is an extensively 
used chemotherapeutic agent for the treatment of a wide variety of cancers, including 
leukemia, stomach, breast, and ovarian157. Treatment with this chemotherapy is associated 
with cardiotoxicity, nephrotoxicity, and hepatotoxicity, in addition to other severe and 
unpleasant side effects72. Doxorubicin’s negative effects on adipose tissue function may 
                                                           
3 3 Murphy, K.P., Patterson, A.T., Montalvo, R. Hall, H.E., Carter, G.J., Smuder, A.J., 
Gower, R.M. To be submitted to Experimental Phsyiology. 
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play a role in cachexia development; however, only few pre-clinical studies have 
characterized the impact of doxorubicin treatment on adipose tissue function71–73.  
 Adipose tissue is most notably known for its role as a lipid storage site, but this 
tissue also controls metabolism, immunity, reproduction, and many other processes 
required for homeostasis through the factors it 8,12,158,159. Therefore, dysfunction of this 
tissue can lead to a host of systemic complications, such as chronic systemic inflammation 
and insulin resistance, which contribute to a type 2 diabetic like state. Biopsies from 
cachexic cancer patients have presented with subcutaneous adipose tissue architectural 
remodeling, such as decreased adipocyte area, increased inflammatory cell infiltration, and 
fibrosis74. Fibrosis is defined as the excessive deposition of extracellular matrix proteins, 
including collagen 1, which is a key provider of the major structural framework of adipose 
tissue160. During obesity related fibrosis, macrophages recruited to the site of injury are 
known to be the key regulator of fibrosis75. These cells produce soluble factors, such as 
TGF-B1, that activate fibroblasts already within the tissue as well as factors that recruit 
new fibroblasts75. Activated fibroblasts possess an increase in α-smooth muscle actin and 
lay down extracellular matrix proteins, such as collagen 1161. Fibrosis has significantly 
negative consequences to adipose tissue function and as a result to systemic processes 
controlled by the adipose tissue75. Fibrosis limits cell to cell communication required for 
proper function and induces a rigidness that reduces flexibility, resulting in decreased lipid 
storage capacity and consequently lipid deposition in distant tissues75. This rigidness is also 
likely to be uncomfortable for the patient leading to a decreased quality of life. 
Furthermore, fibrosis alters the adipose tissue secretome by reducing the secretion of health 
promoting factors, such as adiponectin, which promotes insulin resistance75.  
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 There is limited literature investigating doxorubicin’s impact on adipocyte lipid 
metabolism71–73,162,163; however, even fewer studies have aimed to understand 
doxorubicin’s role in promoting adipose tissue remodeling similar to that observed in 
cachexic cancer patients71. Furthermore, there are several critical, unanswered questions 
that should be addressed regarding the role of doxorubicin administered dose, dosing 
schedule, and the gender of the studied population. To date, most in vivo work studying 
doxorubicin’s effect on adipose tissue has been tested in male rodents by injecting small 
dosages multiple times over several weeks. However, this does not accurately model 
clinical dosages of most cancer patients. A common patient dose of doxorubicin is 60 
mg/m2 administered once every 21 days, therefore, when scaled to rodents this is equivalent 
to a 20 mg/kg dose164. However, it is unknown how adipose tissue responds to this larger 
bolus after 72 hours, since only few have assessed larger dose at early time points165. 
Furthermore, there is a significant need to study the effect of this chemotherapy on adipose 
tissue in female rodents, as to our knowledge this response has never been reported. Since 
doxorubicin is used to treat several female cancer, such as breast and ovarian cancer157, 
and adipose tissue wasting is associated with worsened prognosis in ovarian cancer 
patients156, it is imperative that doxorubicin’s role to promote adipose tissue dysfunction 
in females is investigated.  
Therefore, to begin to address these gaps in literature, the overall aim of this 
manuscript was to characterize the effects of a clinically relevant bolus of doxorubicin on 
adipose tissue fibrosis in female rats. Visceral and subcutaneous adipose tissue depots were 
studied to determine if anatomical location was a factor involved in the extensiveness of 
doxorubicin induced fibrosis, a response not yet investigated. This work is expected to 
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provide greater understanding of doxorubicin’s potential role in promoting cancer-
associated cachexia and provide insight for the development of future strategies to sustain 
adipose tissue health during chemotherapy treatment.  
4.2 Materials and Methods 
4.2.1 Animal Study Design  
The Animal Care and Use Committee of the University of South Carolina approved 
these experiments. Adult four-six-month old female Sprague-Dawley rats were maintained 
on a 12:12 h reverse light-dark cycle and provided rat chow and water ad libitum. Figure 
4.1A illustrates the timeline of the study. A cohort of Sprague-Dawley female rats were 
weighed on day 0 and then randomly assigned to either receive a bolus of doxorubicin 
hydrochloride (20 mg/kg body weight) via intraperitoneal injection or equal volumes of 
saline. Animals were monitored daily. Due to a decline in animal health, the number of 
animals actually studied in each group was reduced. Furthermore, the end point of the study 
was changed from 14 to 9 days due to animal health. At the end of the study, 5 animals that 
had received doxorubicin and 6 animals that received equal volumes of saline were studied.  
On day 9, animals were weighed and then acutely anesthetized with sodium 
pentobarbital (60 mg/kg intraperitoneally). After reaching a surgical plane of anesthesia, 
the heart was removed for mechanistic studies conducted by the Smuder group. Following 
euthanasia, approximately 200-400 mg of the ovarian or inguinal fat pads were submerged 
in 4% paraformaldehyde for histological analysis. The rest of the ovarian and inguinal fat 
pads were flash frozen in liquid nitrogen and stored at -80°C for protein or triglyceride 
analysis.  
 
85 
4.2.2 Histological Analysis 
Ovarian and inguinal fat was fixed in 4% paraformaldehyde, embedded in paraffin, 
and serially cross-sectioned into 5 µm sections. Sections were stained with hematoxylin 
and eosin (H&E) for morphological analysis. Using a Nikon Eclipse ci microscope, three 
random images were taken at 20x magnification of four sections per fat pad per animal. 
Image J software was used to quantify adipocyte area from 4 sections per tissue from 4 
saline injected animals and 5 Dox treated animals. All adipocytes within the field of view 
were quantified. Adipocyte number in each field of view is also reported.  
4.2.3 Triglyceride Quantification  
Triglycerides in ovarian and inguinal fat were quantified using the Triglyceride 
Colorimetric Assay kit purchased from Cayman Chemical. The measurements were made 
according to the manufacturer’s instructions. Briefly, frozen fat pads (150 mg) were 
homogenized in 750 µL of diluted NP40 Substitute Assay Reagent containing Halt 
Protease Inhibitor Cocktail (Thermo Fisher Scientific) using a benchtop homogenizer. 
Samples were centrifuged at 10,000 x g for 10 minutes at 4 °C and the supernatant was 
collected and stored at -80°C until analyzed. Samples were added to a 96-well plate and a 
coupled enzymatic reaction was initiated to hydrolyze triglycerides in the samples to 
produce glycerol and fatty acids. After a 15-minute incubation, the plate was analyzed at 
540 nm using a spectrophotometer. A standard curve was used to extrapolate triglyceride 
concentration in mg/dl in the unknown samples. Triglyceride content was reported as mg 
triglyceride per g homogenized tissue. 
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4.2.4 Protein Quantification  
Frozen fat pads (approximately 500 grams) were homogenized in a defined volume 
of RIPA buffer (Fisher Scientific) containing Halt Protease Inhibitor Cocktail (Thermo 
Fisher Scientific), PhosStop (Sigma), and PMSF (Thermo Fisher Scientific) using a 
benchtop homogenizer. Centrifugation was used to removal all insoluble material and the 
supernatant was collected, aliquoted, and stored at -80 °C. Total protein in the homogenate 
was quantified using the Pierce BCA protein assay kit (Thermo Fisher Scientific). Total 
protein is reported as mg protein per gram of homogenized tissue.  
4.2.5 Western Blotting  
Ten-thirty µg protein was separated by 8% polyacrylamide gel electrophoresis and 
then transferred to 0.2 µm nitrocellulose membranes. Membranes were then blocked with 
5% nonfat dry milk in Tris-buffered saline containing Tween-20 (TBST) for 1 hour at room 
temperature. Primary antibody for anti-collagen 1 (Abcam) and anti-α smooth muscle actin 
(Cell Signaling Technologies) was added to each blot at 1:1000 dilution in 5% BSA in 
TBST and allowed to incubate overnight at 4°C before incubation with a polyclonal 
secondary antibody conjugated to horseradish peroxidase (Abcam) in 5% milk for 1 hour 
at room temperature. The blots were developed with SuperSignal enhanced 
chemiluminescent substrate solution (Thermo Fisher Scientific). To verify loading, blots 
were incubated with stripping buffer for 25 minutes and washed with TBST. The blot 
underwent the same protocol as previously stated for β-actin (Sigma) using a monoclonal 
secondary antibody conjugated to horseradish peroxidase (Biorad). ImageLabs software 
was used to analyze the relative intensity of each protein. Results were reported as intensity 
of the primary antibody relative to the intensity of β-actin.  
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4.2.6 Statistical Analysis 
Statistically significant differences between saline and Dox treated groups were 
evaluated using an unpaired student’s t-test. Statistical significance was set to a p value 
less than 0.05. The number of samples analyzed is detailed in each figure legend. All 
analyses were completed using GraphPad Prism. In all figures, data is presented as 
individual data points from each rat analyzed with mean and standard deviation.  
4.3 Results 
4.3.1 Effect of Doxorubicin on Animal Body Weight and Fat Pad Mass 
 As anticipated, a 20 mg/kg intraperitoneal Dox bolus significantly reduced the body 
weight of treated animals compared to the saline group 9 days after administration (Figure 
4.1B). Additionally, Dox reduced animal body weight by approximately 20% when 
comparing body weight measured prior to injection and before euthanasia on day 9 (Figure 
4.1C). However, to our surprise, the weight of the ovarian (Figure 4.1D) and the inguinal 
(Figure 4.1E) fat pads normalized to body weight did not significantly change 9 days after 
Dox treatment compared to saline injected controls. Additionally, there is significant 
variability between the Dox treated animals in body weight and fat pad weights that is not 
observed in the saline control group. For example, the body weight of Dox treated animals 
changed anywhere from losing 33% of their body weight to gaining 2% of their body 
weight (Figure 4.1B).  
4.3.2 Adipose Tissue Remodeling in Doxorubicin Treated Animals 
 Since cancer induced cachexia patients present with changes in adipose tissue 
remodeling such as extracellular matrix deposition, cellular infiltration, and reduced 
adipocyte area74, both the ovarian and inguinal fat pads were histologically assessed 9 days 
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after Dox treatment. Figure 4.2 shows representative tissue sections of saline and Dox 
treated ovarian (Figure 4.2A-B) and inguinal (Figure 4.2 C-D) stained with hematoxylin 
and eosin.  We did not detect major differences between ovarian fat collected from saline 
rats compared to healthy ovarian fat (data not shown). Furthermore, we observed a slight 
increase in cellular infiltration (purple arrow), extracellular matrix deposition (yellow 
arrow), and vessel formation (red arrow) surrounding adipocytes in Dox treated ovarian fat 
(Figure 4.2B). Compared to the ovarian fat, the inguinal fat inherently has less adipocytes, 
larger intercellular space, increased blood vessels (red arrow), and an inherent abundance 
of collagen fibers (yellow arrows) as seen in inguinal fat collected from saline treated rats 
(Figure 2.4 C). Doxorubicin treatment enhanced the abundance of extracellular matrix 
proteins within the inguinal fat compared to saline control (Figure 4.2D compared to C). 
Furthermore, Dox treatment established a more severe fibrotic response in the inguinal fat 
compared to the ovarian fat, as supported by a significant increase in extracellular matrix 
deposition in Figure 4.2D compared to Figure 4.2B.  
 As a quantitative, surrogate method to measure the extent of fibrosis in both tissues 
as a function of Dox treatment, total protein content in both fat pads was measured (Figure 
4.3). Total protein was not significantly altered with Dox treatment compared to saline in 
either ovarian or inguinal fat, but there was an upward trend observed in both tissues.  As 
observed in the weight measurements, there was large variability in this measurement 
between the Dox treated animals. Similarly, the extent to which Dox induced fibrosis in 
the inguinal fat as observed histologically was highly variable. The image shown in Figure 
4.2D is deemed as the average extent of fibrosis and is associated with the individual data 
point closest to the average total protein content in Figure 4.3B. Large variability was not 
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observed histologically between Dox treated ovarian fat pads, likely because Dox induced 
inflammation was not as severe in this fat pad compared to the inguinal.  
 Upon this observation, we investigated a possible mechanism for the severe fibrosis 
that occurred in inguinal fat pads by measuring collagen 1 and α-smooth muscle actin (α-
SMA) within inguinal adipose tissue homogenate using western blot (Figure 4.4A). 
Interestingly, both collagen 1 (Figure 4.4B, p=0.042) and α-SMA (Figure 4.4C, p=0.054) 
relative to β-actin were significantly increased in inguinal fat pads collected from Dox 
treated animals as determined by an unpaired student’s t-test. This data suggests a possible 
role of activated fibroblasts in this fibrotic response induced by Dox treatment that warrants 
further dissection.  
4.3.3 Adipocyte Morphological Changes in Doxorubicin Treated Animals 
 Adipose tissue function is highly dictated by adipocyte function; therefore, we then 
investigated how Dox treatment altered adipocyte area and number in ovarian and inguinal 
fat pads by further investigating H&E stained sections shown in Figure 4.2. Adipocytes in 
ovarian fat pads collected from Dox treated animals looked to be smaller (Figure 4.5A 
compared to B); however, upon quantification using ImageJ, adipocytes were not 
significantly smaller in area compared to the saline treated group (Figure 4.5E), but there 
was a decreasing trend observed. However, there were significantly more adipocytes within 
each frame indicating a potential state of hyperplasia (Figure 4.5F). Similarly, adipocytes 
in inguinal fat pads collected from Dox treated animals also appeared to be smaller in 
stained sections (Figure 4.5C compared to D); however, upon quantification there was not 
a significant difference in adipocyte area or number between groups. Once again, we 
observed large variability in the quantification between Dox treated animals, especially in 
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the inguinal fat analysis. The histological image in Figure 4.5D is associated with the 
individual data point in Figure4.5G and H closest to the mean. To test the hypothesis that 
Dox treatment reduced triglyceride content as suggested by a reduction in adipocyte area, 
we measured total triglyceride content in each tissue (Figure 4.6). In ovarian and inguinal 
fat, triglyceride content was not significantly reduced with Dox treatment, and in fact 
trended upward compared to saline injected animals. To our surprise, the animals that 
exhibited smaller adipocyte area measured to have more triglycerides within the tissue.   
4.4 Discussion 
 Cachexia is a significant symptom of cancer progression that leads to 
approximately 20% of cancer-related deaths and a major reduction in the patient’s quality 
of life. Because patients that receive cytotoxic chemotherapy treatments often present with 
changes in body mass and composition155, it is likely that chemotherapy plays a role in 
progressing this condition.  Doxorubicin is a widely used chemotherapeutic with severe 
cytotoxic effects on the heart, liver, and kidney157; however, the role of doxorubicin 
administration on adipose tissue wasting remains unclear. In this report, we demonstrated 
that a 20 mg/kg bolus of Dox significantly reduced body weight, but not adipose tissue 
weight, and differentially promoted fibrosis of adipose tissue depots 9 days after injection 
in female rats. To our knowledge, these results are the first to suggest that Dox induced 
adipose tissue fibrosis also occurs in female rodents and varies based on adipose tissue 
anatomical location.  
 Our results indicate a significant importance of Dox administration, such as dose 
and study duration, on adipose tissue function. A single 20 mg/kg doxorubicin bolus was 
chosen for this study because it represents a relevant clinical human dose scaled to rodents. 
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This dose has been used to evaluate Dox effects on skeletal muscle166 and heart165; 
however, the effect of Dox on adipose tissue at this dose has yet to be investigated. Our 
results indicate 9 days after injection, Dox significantly reduced animal body weight, which 
is a similar response demonstrated by studies that administered this dose, but ended the 
study 24-72 hours after injection165,167. Furthermore, our results did not indicate a 
significant reduction in ovarian (perigonadal) or inguinal (subcutaneous) fat or adipocyte 
area in either tissue. We hypothesize that body weight changed due to Dox induced changes 
in other organs such as skeletal muscle166. Contrary to our results, when 2.5 mg/kg Dox 
was administered twice per week for two weeks, rodents maintained their body weight, 
significantly lost perigonadal and subcutaneous adipose tissue mass, and observed a 
significant reduction in adipocyte area in subcutaneous tissue71. However, when 
administering Dox as either a single, large bolus or multiple small injections, fibrosis 
occurred in subcutaneous tissue and was associated with an increase in collagen71.  This 
leads to the conclusion that dose and administration schedule may have an impact on how 
Dox impacts adipose tissue.  
 Pre-clinical studies have determined that Dox induces fibrosis and inflammation in 
several organs, such as the liver168 and heart169, but there is limited knowledge on Dox’s 
fibrotic effect on adipose tissue. Similar to a previous report71, we demonstrated that a Dox 
bolus induced fibrosis in subcutaneous adipose tissue. Dox induced adipose tissue fibrosis 
was associated with an elevation in collagen 1 and α-smooth muscle actin expression, a 
marker of activated fibroblasts161. Therefore, we propose the mechanism of this response 
may be two-fold: 1) Dox stimulates the infiltration of macrophages that in turn activate 
fibroblasts to synthesize extracellular matrix proteins via secreted soluble factors and/or 2) 
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Dox directly activates fibroblasts to synthesize extracellular matrix proteins. This 
hypothesis is supported by literature suggesting that Dox treatment increases infiltration of 
macrophages at injured site, as observed in Dox induced nephropathy170, and also activates 
cardiac fibroblasts which led to an elevation in α-smooth muscle actin expression and 
collagen 1 expression171.  Additionally, this fibrotic response was similar to that in 
subcutaneous adipose tissue biopsies from cancer cachexic patients characterized by an 
elevation in collagen 1, α-smooth muscle actin74,172. Furthermore, cachexic patient biopsies 
also indicated altered TGF-β signaling, suggesting a possible role for TGF-β in Dox 
induced adipose tissue fibrosis, which should be a focus of future studies.  
 Furthermore, in this report, we established for the first time that Dox more severely 
induces a fibrotic response in inguinal fat, a subcutaneous fat pad, compared to ovarian fat, 
a visceral fat pad, in female rats. This is particularly interesting because in this study Dox 
was administered intraperitoneally, where the ovarian fat was bathed in the drug upon 
injection. We hypothesize that inherent differences in composition and function between 
visceral and subcutaneous fat pads may play a role in this altered effect. One such 
difference is that subcutaneous fat has higher basal levels of PPARγ, a nuclear receptor 
involved in adipocyte differentiation and is also more responsive to PPARγ ligands, such 
as thiazolidinediones34,173.  If this tissue is more responsive to PPARγ ligands, then it’s 
possible that it could be more sensitive to agents that inhibit PPARγ, such as Dox174. 
Additionally, activation of PPARγ can block TGF-β signaling and thus fibrosis175.  
Therefore, the subcutaneous fat may be more fibrotic due its heightened sensitivity to 
PPARγ inhibition after Dox leading to the enhanced TGF-β induced fibrosis.  
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 The data set reported here exhibited large variability associated with the Dox 
treated animals. It is hypothesized that this large variability is associated with the use of 
female rats in the study. This is the first time that adipose tissue dysfunction has been 
reported in female rats; however, in a study using male rodents, there doesn’t appear to be 
large variances in data collected from adipose tissue, even when using a small sample 
size71. Sexual dimorphism has been established in Dox induced toxicities as female rodents 
have shown to be protected against Dox induced cardiotoxicity compared to males176. 
Therefore, some animals appeared to be more resistant than others to Dox treatment 
potentially due to differences associated with the fact that they are female. Furthermore, 
fluctuations in female reproductive hormones in response to estrous cycles could 
complicate the system and potentially be a source of data variability between Dox treated 
animals. Fluctuations in sex hormones plays a significant role in adipose tissue metabolic 
function; for example, a decrease in estrogen is associated with an increase in fat pad 
weight177. Further investigation is warranted on sexual dimorphism and the role of female 
sex hormones on Dox induced adipose tissue dysfunction. This is especially important to 
understand for ovarian cancer patients, a population in which chemotherapy induced 
adipose tissue wasting is associated with lower survival156.  
 Since adipose tissue wasting is a main component of cancer associated cachexia, 
and is in part due to toxic chemotherapies, there is a significant need for novel therapies to 
sustain adipose tissue health and metabolic function during chemotherapy treatment. We 
propose in future studies to utilize particle delivery systems that are easily injected into the 
subcutaneous fat pad to target macrophages as a strategy to prevent doxorubicin induce 
adipose tissue fibrosis. The results presented here indicate that a chronic Dox bolus maybe 
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an appropriate therapeutic testing model for the development of adipose tissue fibrosis in 
female cancer patients; however, to maintain 100% animal survival, further investigation 
into adipose tissue dysfunction of clinically relevant dosage and schedules is needed. 
 
4.5 Figures  
 
 
 
 
Figure 4.1: Study timeline, body weight change, and fat pad mass 9 days after Dox 
administration. (A) Study timeline. (B-C) Body weight (B) and body weight percent 
change (C).  (D-E) Ovarian (D) and inguinal (E) adipose tissue mass. Data is from n=5 
Dox treated animals and n=6 saline controls. Data is presented as individual data points 
with mean ± standard deviation.  
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Figure 4.2: OWAT and IWAT histological analysis. (A-D) Histological sections of 
ovarian (A,B) and inguinal (C,D) fat pads collected 9 days after saline (A,C) and Dox 
(B,D) injection stained with hematoxylin and eosins. Scale bar represents 500 µm.  
 
Figure 4.3: Effect of Dox administration on total protein content 9 days after 
injection. Protein content measured in (A) ovarian and (B) inguinal fat pads. Data is 
collected from n=6 saline injected rats and n=5 Dox treated rats. Statistics determined 
using an unpaired student’s t-test.  
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Figure 4.4: Effect of Dox administration on profibrotic proteins. (A) Representative 
western blots of collagen 1 and α-smooth muscle actin expression in inguinal adipose 
homogenate 9 days after treatment. (B-C) Quantification of (B) collagen 1 and (C) α-
smooth muscle. Data is collected from n=6 saline injected rats and n=5 Dox treated rats. 
Statistics determined using unpaired student’s t-test. * indicates p<0.05 compared to 
saline.  
 
Figure 4.5: OWAT and IWAT adipocyte area and number 9 days after Dox 
administration. (A-D) Histological sections of ovarian (A,B) and inguinal (C,D) fat 
pads collected 9 days after saline (A,C) and Dox (B,D) injection stained with 
hematoxylin and eosin. Scale bar represents 100 µm. (E-H) Quantification of adipocyte 
area (E,G) and number (F,H) from ovarian (E,F) and inguinal (G,H) fat pads. Data was 
collected from 3 random 20x images per section, with 4 sections per fat pad, and 4-5 
rats per group. Statistics determined using an unpaired student’s t-test. * indicates 
p<0.05. 
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Figure 4.6: Effect of Dox administration on triglyceride content 9 days after 
administration. Triglyceride content was measured in (A) ovarian and (B) inguinal fat 
pads.  Data is collected from n=6 saline injected rats and n=5 Dox treated rats. Statistics 
determined using an unpaired student’s t-test.  
 
98 
CHAPTER 5 
CONCLUDING REMARKS AND FUTURE DIRECTIONS 
5.1 Concluding Remarks 
 Once known as an inert site for lipid storage, the adipose tissue has recently become 
well accepted as an endocrine organ that plays a key role in whole body homeostasis. The 
ability to directly modulate its inherent endocrine and metabolic functions has promising 
implications in treating diseases associated with adipose tissue dysfunction. One such 
example is obesity, in which a significant portion of the United States adult population has 
been diagnosed, a trend that continues to rise. Since obesity is a critical risk factor for 
numerous severe and chronic diseases, this epidemic has become an ever increasing 
economic and health burden. With the current interventions possessing substantial 
challenges, novel therapeutic platforms engineered to specifically target the adipose 
tissue’s metabolic and endocrine function are warranted. One central objective of this work 
was to test the effectiveness of scaffold-based delivery of resveratrol, a promising anti-
obesity drug that suffers from poor bioavailability, to reduce inflammation and lipid 
accumulation upon implant into the adipose tissue and thus establish its potential as an anti-
obesity therapeutic platform.  
 The first aim accomplished this objective by further understanding how the immune 
compartment within the adipose tissue was altered after poly(lactide-co-glycolide) scaffold 
implant and how the incorporation of resveratrol modulated this response. This was 
particularly important to understand as inflammation drives metabolic disease within the 
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adipose tissue. Resveratrol was successfully incorporated into the polymer matrix with 
high resveratrol loading and exhibited a drug release with a burst followed by a plateau 
phase. In addition, resveratrol loaded materials maintained their loading and activity for at 
least a year. The in vivo results of this aim, outlined in Chapter 2, demonstrated that the 
incorporation of resveratrol augments an anti-inflammatory environment established by 
PLG scaffolds, characterized by low levels of pro-inflammatory cytokines and increased 
expression of anti-inflammatory cytokines upon implant in lean mice. More therapeutically 
relevant were the results that treatment with resveratrol scaffolds decreased inflammatory 
cytokines in mice challenged with a high fat diet and adipocytes treated with a 
inflammatory stimulus. This work demonstrates to the tissue engineering community that 
PLG scaffolds are a promising platform for the treatment of adipose tissue inflammation, 
which drives metabolic disease, due to their ability to promote an anti-inflammatory 
environment and their feasibility to be engineered as drug delivery vehicles.  
 The goal of the second aim, described in Chapter 3, was to investigate resveratrol 
scaffold-based delivery to enhance lipid catabolism within the adipose tissue. Implant of 
resveratrol scaffolds in lean mice decreased adipocyte size relative to scaffolds with no 
drug pay load, which is a surrogate measurement of lipid load within the cells. Furthermore, 
the results support the hypothesis that resveratrol scaffolds decrease adipocyte size because 
resveratrol increases lipid utilization in scaffold-infiltrating immune cells, potentially by 
elevating expression or activity of the rate limiting enzyme in fatty acid oxidation. 
Importantly, mice pre-treated with resveratrol scaffolds prior to high fat diet feeding 
exhibited decreased weight gain, adipose tissue expansion, and adipocyte hypertrophy 
compared to scaffolds without a drug payload. This was the first study of its kind to indicate 
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that a single administration of resveratrol via PLG scaffold delivery was as successful in 
preventing weight gain compared to the daily regiment generally needed for oral delivery. 
These results indicate that localized delivery of metabolism modulating agents directly to 
the tissue of interest may overcome poor bioavailability. Taken together with the results 
described in Chapter 2, this work demonstrates to the tissue engineering field that PLG 
scaffolds are not only a suitable platform for adipose tissue regeneration and in vitro model 
development, but also a promising platform for local drug delivery to the adipose tissue. 
Furthermore, this strategy has the potential to be a promising therapeutic anti-obesity 
strategy through its ability to direct adipose tissue inflammatory and metabolic programs. 
 In addition to obesity, cachexia is a debilitating disease that is associated with 
adipose tissue wasting and inflammation and decreases the quality of life for a significant 
number of cancer patients. In the work described in chapter 4, we aimed to establish how 
a doxorubicin bolus impacted adipose tissue remodeling in female mice, a response that 
had yet to be reported, but is significant since a large portion of doxorubicin treated patients 
are women. Doxorubicin treatment significantly reduced body weight, but treatment did 
not decrease adipose tissue mass or adipocyte area. Furthermore, significant fibrosis 
occurred in subcutaneous adipose tissue to a greater extent than visceral that was associated 
with an increase in expression of a fibroblast activation marker and collagen, a response 
similarly found in human cachexia patients.  These results provide further understanding 
of how chemotherapy can potentially promote cachexia, a disease that leads to 20% of 
cancer deaths. Furthermore, this work may provide insight for the development of future 
platforms to sustain adipose tissue health during chemotherapy treatment.  
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5.2 Future Directions   
 While Chapters 2 and 3 undoubtedly demonstrate that resveratrol loaded scaffold 
delivery is a promising strategy for directing adipose tissue function, there are several 
challenges that this strategy must overcome in order to increase its future translatability. 
Overcoming these challenges should be a major focus of future work. The first challenge 
is that as its been studied so far, the implantation process requires an invasive surgical 
procedure in which the abdominal cavity is opened. This could be alleviated in two ways: 
1) target a subcutaneous fat pad or 2) develop an injectable system that would not require 
an implant surgery. Targeting a subcutaneous fat pad would allow for the scaffold to be 
implanted via a small incision and a trocar. However, this strategy has not been studied in 
subcutaneous fat pads; therefore, we do not know if this strategy will have the same 
beneficial effects in subcutaneous fat due to differences in composition and metabolic 
activity in visceral and subcutaneous fat depots. Additionally, developing an injectable 
system would bypass the need for surgical procedures and would allow for targeting of any 
fat depot.  
Secondly, this strategy is associated with extensive remodeling where the immune 
system encapsulates the material due to its inability to remove the material. As elaborated 
on in Chapter 4, this fibrotic response can have negative effects on adipose tissue function. 
Therefore, future work should focus on developing an injectable technology that would 
also not induce extensive remodeling. Literature suggests that a promising strategy would 
be to develop a particle system that would rather individually target immune cells to 
modulate gene programs involved in inflammation and metabolism.  
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Finally, the release kinetics of resveratrol from the scaffold should be improved. 
The current fabrication technique results in a scaffold that is loaded with a large amount of 
resveratrol that releases in a burst phase followed by a plateau phase. This was strategic 
when desiring to modulate the acute inflammatory phase which occurs in the first few days 
following implant; however, it is likely that extended release over longer periods of time 
will enhance its effectiveness as a therapeutic for metabolic disease. Furthermore, even 
though we saw an increase in anti-inflammatory cytokines in Chapter 2, an initial increase 
in neutrophils occurred that was likely counterproductive and potentially due to the burst 
release of resveratrol from the scaffold. Fabrication parameters that could be tailored in 
order to extend this release are polymer molecular weight and the amount of resveratrol 
loaded within the scaffold. Increasing the polymer molecular weight and decreasing the 
amount of resveratrol loaded is likely to reduce the burst release and extend the release 
from the scaffold over time.  
In Chapter 4, the effect of Doxorubicin to induce adipose tissue fibrosis in female 
rats was demonstrated. In the model used in this study, the dose and study timeframe were 
associated with decreased animal survival. Therefore, further understanding of the adipose 
tissue fibrosis that results after i.p. injection of a clinically relevant dose given for a shorter 
time is likely necessary to maintain animal survival. Furthermore, there is a therapeutic 
opportunity to use biomaterials to sustain adipose tissue health during chemotherapy 
treatment. Therefore, a particle drug delivery system could be designed to inhibit fibrosis 
by locally delivering a potent anti-inflammatory molecule or targeting macrophage 
inflammatory function. This doxorubicin induced fibrosis model could be utilized to test 
the efficacy of these therapeutic systems in future studies. Collectively, the future 
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improvements and studies discussed could lead to the development of potentially life-
saving therapeutic strategies for adipose tissue dysfunction associated with obesity and 
cachexia.  
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APPENDIX A 
BEST PRACTICES FOR WESTERN BLOTTING 
Western blotting is a technique that is extensively used in biological research to 
determine relative expression of specific proteins in the sample. There are several online 
resources that one can take advantage of to learn this technique (doi:10.4103/1947-
2714.100998, 10.1111/sms.12702, and Biorad’s Introduction to Western Blotting 
webpage). However, over the course of my Ph.D., I have analyzed lysate from cell culture 
experiments and collected adipose tissue from animal experiments and the techniques that 
I have learned while running these experiments are detailed below.  
A.1 Sample collection and storage 
 When analyzing protein from either cells or tissues, the first thing that must be done 
is to isolate the protein fraction from your sample. There is a specific protocol for cells 
collected from cell culture and tissues collected from animal studies. The homogenization 
buffer consisting of RIPA buffer, 100x PhosStop, 100x PMSF, and 100x protease inhibitor 
cocktail is the same for both samples. To lyse RAW 264.7 cells, 100 µL of the 
homogenization buffer should be added to each sample for experiments where more than 
200,000 cells were seeded. I would suggest decreasing the cell volume to 75 µL for 
experiments where fewer than 200,000 Raw 264.7 cells were seeded. When using 3T3-L1 
cells, experiments with 80,000 cells per well or greater can be homogenized in 100 µL. 
Cells are then lysed using a needle and syringe. Do not create bubbles during lysing. The 
homogenized cells are then centrifuged and the supernatant (protein fraction) is collected 
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from the top. Be careful not to disturb the pellet at the bottom. Supernatant is aliquoted into 
appropriately labeled tubes and stored in the -80°C freezer 
For tissues, the tissues are first weighed (usually this is done upon collection from 
the animal prior to freezing) and placed into a 2 mL round bottom tube. It is important that 
they are placed in a round bottom tube because the homogenizer tip can fully reach the 
bottom of the tube during homogenization, which it cannot when using a 1.7 mL conical 
tube. The samples are to be kept on ice at all times. Homogenization buffer is added to the 
tissue at a volume (µL) that is 4 x tissue mass (mg). If the tissue is larger than 250 mg 
(addition of 1mL buffer), I suggest splitting the tissue into multiple 2 mL round bottom 
tubes. This will ensure that the liquid does not overflow during homogenization. A pair of 
surgical scissors is then used to finely mince each tissue and the samples are then placed 
on the rocker in the fridge for 45 minutes. Be sure that when they are placed on the rocker, 
they are placed longways and ensure that the solution is moving up and down within the 
tube. The large homogenizer tip used for particle fabrication should be exchanged for the 
smaller tip and cleaned with ethanol and water prior to homogenization. Be sure to have 
reserved the homogenizer on the google calendar or talked with lab mates prior to planning 
the homogenization. Each sample will be homogenized for 3x1min at 10,000 rpm. I suggest 
homogenizing each sample in one experimental group once and then repeating all of them 
2 more times. This will ensure each sample stays as cold as possible. The homogenizer 
must be cleaned between each sample using water and ethanol. The microcentrifuge should 
be “fast temped” to 4°C prior to centrifugation of samples at 18,000 xg for 45 minutes. 
Supernatant is collected from samples, aliquoted into appropriately labeled tubes and 
stored in -80°C freezer. Be sure not to disturb the pellet at the bottom. For fatty tissues, 
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such as adipose tissue, there will also be an insoluble fatty cake on the top. I found that the 
easiest way to deal with this layer is to push it to the side or even out using a 1000 µL 
pipette tip.  
A.2 Total protein analysis    
 In order to appropriately compare the result from each sample, the amount of total 
protein analyzed must be the same for each sample. Therefore, a BCA assay is used to 
determine the amount of total protein in each sample. A 2 mg/mL bovine serum albumin 
aliquot is diluted in homogenization buffer to create a standard curve to which the unknown 
samples will be compared. Usually, each sample is added to the 96 well plate using a 1:5 
or 1:2 ratio of sample to homogenization buffer based on the concentration of the sample 
and where it falls on the standard curve. Be sure to add each standard and sample on the 
plate in duplicate, at least.  Solution A and B provided in the kit are mixed in a 1:50 ratio 
of solution B to A and 200 µL of the mixture is added to each well. I would recommend 
using a 300 µL multichannel pipette to do this as quickly and uniform as possible. This is 
a light sensitive reaction; therefore, be sure to cover the plate and place it in aluminum foil 
on the slow rocker. After 30 minutes, the plate is ran at 562 nm on the Spectramax located 
in Catawba. Since the volume of each well is important when reading the absorbance, be 
careful when transporting the plate across the street. Generally, I have found that there is 
2-3 mg/mL protein isolated from epididymal fat collected from chow fed healthy male 
C57Bl/6 mice, 4.5 mg/ml protein per 1x106 Raw 264.7 cells, 5 mg/ml protein per 1x106 
3T3-L1 undifferentiated cells, and 13 mg/ml protein per 1x106 3T3-L1 differentiated cells 
when cells were lysed in 100 µL of buffer. 
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 Once you have the absorbance values for the plate, upload them in Excel. The 
standard curve will be plotted with the x axis as absorbance and y axis as concentration. 
Be sure to average the absorbance values for each standard and subtract the background (0 
mg/mL) from each prior to plotting. Add a linear trendline and equation to the graph. The 
R2 value should be greater than 0.98. If it isn’t or you see that duplicate samples are not 
similar, then I suggest repeating the assay and be sure to watch out for any pipetting errors. 
The equation can then be used to solve for protein concentration (mg/mL) in the unknown 
samples by plugging in the average absorbance value for each unknown (after subtracting 
the background).  
 The amount of protein that you need to load to the gel will be dependent on the 
protein of interest that you are analyzing. I suggest conducting an optimization western 
blot where you analyze one sample from each group at different protein amounts loaded to 
the gel in order to determine the appropriate loading amount. I suggest adding a positive 
control in this optimization experiment as well. I had much success contacting Cell 
Signaling for free positive controls for several antibodies. Most proteins that I have 
analyzed in adipose tissue and cell lysate have been successful when adding 10-30 µg to 
the gel.  
To determine the volume of each sample needed to add to the gel (µL) that will 
provide the appropriate amount of protein, divide the amount of protein that should be 
added to the gel (µg) by the total concentration (µg/µL). The protein concentration and the 
amount of protein desired to load will determine the total volume that should be added to 
the gel. If it is greater than 25 µL, then the 10 well comb should be used during gel casting 
as it can accommodate up to 45 µL. If 25 µL or less can be loaded and you have more than 
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10 samples, the 15 well comb can be used during gel casting. The amount of sample buffer 
(2X Biorad sample buffer+ β mercaptoethanol) should be half of the total volume. 
Homogenization buffer should be added to make up the difference between the total 
volume, sample, and sample buffer.  
A.3 Gel preparation  
 The molecular weight of the protein of interest will dictate the percentage of 
acrylamide in the gel that is used, such that the molecular weight and acrylamide 
percentage are inversely proportional. When probing for higher molecular weight proteins 
(100-250) kDa, I suggest casting an 8% acrylamide gel to ensure the greatest separation 
between the top three standards. However, most of the proteins that we probe for will be 
successful using a 10% gel (25-100 kDa). For smaller proteins, I suggest using a 15% 
acrylamide gel. The separation gel is first made at the appropriate acrylamide percentage 
using the recipe found on the google drive. Once the casting apparatus is set up, I suggest 
adding the comb to the top to ensure you are aware how high to pour the stacking gel (it 
should not be poured higher than the comb will allow). Methanol is added to the stacking 
gel solution once it is poured using a 1 mL pipette so to remove any air bubbles. It normally 
takes approximately 25 minutes for the solution to gel, which can be determined by 
observing the leftover solution. Once it is gelled, the extra solution on the top is poured out 
and the stacking gel solution is poured on the separating gel. The stacking gel is casted the 
same way for every gel, no matter the acrylamide percentage. The comb of choice as 
determined by experimental design must be added to the gel solution quickly after pouring. 
Be sure the Biorad emblem on the comb is facing you when you slide it into the apparatus. 
If it is backwards and you try to push it in it will break the glass cast. Furthermore, be sure 
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there are no air bubbles in the comb as this can have a negative impact during well loading 
and electrophoresis.   
A.4 Buffer preparation  
 The main buffers needed to successfully run these experiments are running buffer, 
transfer buffer, and tris buffered saline (TBS) and the recipes for each buffer is found on 
the google drive. I suggest making a 5X stock of running buffer that can be diluted when 
needed. Prior to making this stock, make a 10% solution of sodium dodecyl sulfate (SDS) 
using the heated stir plate that you should then use to add the appropriate amount of SDS 
to the 5x stock. Do not add solid SDS to the 5X running buffer stock as it is extremely 
difficult to dissolve and stocks made with solid SDS have been associated with 
electrophoresis issues. Transfer buffer is usually made the day of the experiment. Be sure 
to pH the buffer prior to adding the appropriate amount of methanol. Most proteins that we 
probe for in our lab require transfer buffer that contains 20% methanol; however, high 
molecular weight proteins (>150 kDa) it is suggested to use transfer buffer containing 10% 
methanol to prevent these proteins from precipitating out. I suggest making a 5X solution 
of TBS using the recipe. To make TBST, the wash buffer, dilute this stock and add 10% 
tween.   
A.5 Sample preparation  
 In order to reduce proteins so that they can be ran on gel electrophoresis, samples 
must be mixed with Laemmli sample buffer supplemented with β-mercaptoethanol and 
heated at 100°C for 5 minutes. Turn the hot plate on first thing to allow ample time to reach 
100°C. To make the sample buffer, first determine the total volume you need for your 
experiment as determined in section A.2 and then make a solution that is 5% β-
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mercaptoethanol in 2x Laemmli sample buffer supplied from Biorad. According to the 
calculations conducted in section A.2, mix the appropriate volumes of protein lysate, RIPA 
buffer, and sample buffer and vortex to mix thoroughly. Make a hole in the cap of each 
sample and place on the heating block for 5 minutes. During these 5 minutes, set up your 
gel electrophoresis station.  
A.6 Gel Electrophoresis  
 To set up your station, put the previously made gels in the gel electrophoresis cell 
with the gel combs facing inward. If you are only running one gel, replace the second gel 
with the running plate to ensure that running buffer will remain within the inner cell. Add 
running buffer to the inner cell all the way to the top of the gel casts and then add running 
buffer to the outside cell until it reaches the two-gel line. Carefully, remove the combs from 
the gel cast and top off the inner cell with running buffer. Once the samples are removed 
from the heating block, vortex the samples thoroughly in order to thoroughly break the 
disulfide bonds. Quickly spin down the samples to collect all of the volume at the bottom. 
I suggest putting the samples in the order in which you plan to load them into the gel as 
this will make it easier to ensure they are in the proper order upon loading. Be careful with 
this because once your samples are loaded, you have no way of confirming which sample 
is in which lane. Add approximately 3 µL of Biorad ladder to the first lane in each well 
and then add the appropriate volume of sample to each lane. Be careful to pipette the same 
volume of each sample as this can cause differences in loaded protein content. Once you 
are finished loading, place the electrophoresis cell lid on top ensuring that the black and 
red rods are inserted into the black and red holes on the lid. Turn the powerpack on and set 
it to 90V for the first 30 minutes and then increase the voltage to 125V until the ladder has 
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separated the entire length of the gel. Bubbles will indicate that the gel is successfully 
running. The time necessary for the gel to run is approximately 1.5 hours for a 10% gel; 
however, this will change based on the acrylamide percentage in the gel. 
A.7 Transfer 
 In my opinion, transfer can be the most difficult aspect of the experiment to perfect; 
therefore, it may take a few trials to become comfortable with this part. First, transfer buffer 
should be made fresh as stated in the protocol. Most proteins require transfer buffer that 
contains 20% methanol; however, extremely high molecular weight proteins (>250), for 
example, acetyl co-A-carboxylase (280 kDa), should be transferred using transfer buffer 
containing 10% methanol, as methanol can cause high molecular weight proteins to 
precipitate out during transfer. Prior to removing the gels from the running tank, place the 
transfer tank in a Styrofoam box, pack ice around the tank, and place an icepack in the 
transfer tank. Then gather the appropriate number of transfer cassettes (red and black) 
(1/gel), black sponges (2/gel), filter paper (2/gel), nitrocellulose membrane (1/gel) and 
transfer container. Be sure to cut the nitrocellulose membrane to as similar size to the gel 
as possible and submerge in transfer buffer.  Submerge the filter paper and black sponges 
in the transfer buffer and then arrange the transfer cassette where the assembly is completed 
on the black portion of the cartridge (i.e. black is closest to you). Once the protein is 
sufficiently separated, gels can be removed from the running tank. Gently crack the gel 
open, scrape off the wells and transfer the gel from the cast into transfer buffer until ready 
to load into the transfer cassette. Then assemble the sponges, gel, membrane, and filter 
paper in the transfer cassette as follows: black sponge, filter paper, gel, nitrocellulose 
membrane, filter paper, and black sponge. Be sure to roll out any air bubbles between each 
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layer to ensure protein transfer. The proteins will transfer from left to right; therefore, when 
you place the assembled cassette in transfer tank it is important for the red side to face to 
the right so that the protein can travel from the gel into the membrane. Add transfer buffer 
until the fill line and run the apparatus at 25V overnight (approximately 17 hours). If 
running multiple gels, be sure to mark down which slot which gel was transferred in. 
Additionally, smaller proteins may over transfer; therefore, for low molecular weight 
proteins (>20 kDa), I suggest transferring for 3 hours instead of overnight.  Once the 
transfer is complete, remove the gel and nitrocellulose membrane and use the gel outline 
to cut any excess membrane. Then remove the membrane, place it in a labeled plastic blot 
container with TBST, and wash for 5 minutes to remove any residual transfer buffer. From 
this point, if the membrane dries out it is unusable; therefore, ensure that the blot is always 
submerged. 
A.8 Immunoblotting  
 In order to block nonspecific binding, add 5% nonfat milk to each blotting container 
and allow to incubate at room temperature on the rocker for 1 hour. Remove the milk and 
wash with TBST for 1 minute to remove all excess milk. Most primary antibodies that we 
purchase from Abcam or Cell Signaling are used at 1:1000 dilution in 5% BSA. Add the 
primary antibody solution to all blots and allow to rock in the refrigerator overnight.  The 
next day, remove the primary antibody and wash in TBST for 20 minutes and repeat 2 more 
times. Primary antibodies will either be grown in rabbit or mouse; therefore, will require 
an anti-rabbit or anti-mouse secondary antibody. Both antibodies are used at 1:2000 
dilution in 5% milk supplemented with 1:5000 dilution of the Biorad ladder secondary. 
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Blots are incubated at room temperature on the rocker for 1 hour and then washed with 
TBST for 4 times 15 minutes.  
A.9 Imaging blot using ChemiDoc  
 The western blot imager is found in Catawba. When turning the machine on be sure 
to turn on the imager and camera a few minutes prior to turning the computer on to ensure 
a connection. Wipe down the imager before and after use with 70% ethanol. Upon opening 
the ImageLab software, take the following actions:  
- New protocol  
- Application -> Select -> Blots -> Chemi hi resolution  
- Imaging Area -> Bio-Rad Criterion Gel  
- Set the appropriate exposure time  
To develop the signal, mix a 1:1 ratio of each component of the chemiluminescent 
substrate. Then exchange the TBST on the blot for chemiluminescent substrate and 
incubate for 2 minutes while rocking the blot. Be sure to do this in the dark to prevent 
photobleaching. Using the forceps, gently place the membrane on the imager and ensure 
its proper positioning by selecting position gel on the software. Once appropriately placed, 
expose the blot for the appropriate amount of time determined by the saturation of the band 
of interest. I suggest using the exposure setting where you set how many images the camera 
takes in a certain time period. Imaging exposure times will vary depending on protein of 
interest. Most proteins that I have measured use an exposure time between 5-60 seconds. 
If the blot needs to be stripped and probed for a different protein, place the blot back in the 
plastic container submerged in TBST to ensure the blot doesn’t dry out. If not, the blot can 
be disposed. 
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A.10 Probing for second protein  
 Wash the blot in TBST for 10 minutes to remove any residual chemiluminescent 
substrate that may still be on the blot and then incubate the blot in 4 mL Biorad stripping 
buffer for 25 minutes at room temperature on the rocker. This stripping buffer contains β-
mercaptoethanol; therefore, it is necessary to excessively wash the blot in TBST to remove 
any residual β-mercaptoethanol that may interfere in the immunoblotting process. I 
recommend washing the blot at least 4 times in TBST for 5 minutes each time. Continue 
the immunoblotting and analysis process as previously stated for the next protein. 
Generally, this is GAPDH or β-actin, which are both incubated at 1:5000 dilutions in 5% 
BSA. GAPDH requires the rabbit secondary antibody and β-actin requires the mouse 
secondary antibody.   
A.11 Analyzing intensity of bands using Image Lab 
 ImageLab software can be downloaded for free directly from the Biorad website so 
that you can analyze the intensity of your band on your own computer. Once you have 
opened the file, select Lane and Bands in the Analysis Toolbox, and then select to manually 
indicate the lanes. Indicate the number of lanes of samples that you will analyze and then 
manipulate the lanes so that each lane contains only one band and is the appropriate width 
for that band. In the newest version of ImageLab, to change the width of the lane, you need 
to select Bands from the Lane and Bands toolbox, select a lane and then return to Lanes. 
Once you have the lanes in the proper place, select Bands, Add and then click on your 
bands on interest. Clicking Adjust in the toolbox will allow you to ensure that the height 
of each band contains the entire band and that all heights are the same. Once this is 
accomplished, click Analysis Table from the top toolbar and a table will be displayed on 
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the bottom of the screen. Copy the adjusted intensity for each lane into a new excel 
spreadsheet and normalize the intensity of the protein of interest by the total protein if 
looking at a phosphorylation site or the housekeeping protein (i.e. GAPDH or β-actin).   
The intensity of the housekeeping protein should be approximately the same between each 
sample on the gel. 
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APPENDIX B 
BEST PRACTICES FOR FLOW CYTOMETRY EXPERIMENTS 
Flow cytometry is a powerful technique that uses cell surface markers to measure 
the prevalence of different cell populations within a parent cellular suspension. During my 
time in the lab, I used flow cytometry to determine the number of different immune cell 
populations found within the adipose tissue after PLG scaffold implant. Additionally, I 
used this tool to determine the purity of porcine derived adipose tissue stem cells and bone 
marrow derived macrophages. This section will go into detail of best practices to ensure 
while conducting flow cytometry experiments.  
B.1 Designing flow cytometry panels and controls 
 When designing a flow cytometry experiment, it is necessary to first determine the 
purpose of the experiment, the cell surface markers needed, and the capabilities of your 
flow cytometer. For this example, the purpose of your experiment is to quantify the number 
of macrophages in the adipose tissue. We must first consider the capabilities of our 
equipment. We use the BD FACS Aria II flow cytometer located at the University of South 
Carolina Medical School. This machine contains 488 and 640 lasers with filters for FITC, 
PE, PE-Texas Red, and PE-Cy7 on the 488 laser and APC and APC-Cy7 on the 640 laser. 
Therefore, your staining cocktail can only contain a maximum of six markers; however, 
we determined that PE-Texas Red and PE signal significantly overlap; therefore, I suggest 
using only FITC, PE, PE-Cy7, APC and APC-Cy7 labeled antibodies in the development 
of your panel. The commonly used surface markers for macrophages is CD11b and F4/80.
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 However, you determine that you need to first isolate the immune cells within the tissue; 
therefore, you also need CD45 as a global immune cell marker. Therefore, you need three 
antibodies each labeled with a different fluorochrome that can be analyzed by the flow 
cytometer. If you had decided to quantify several immune cell populations including 
macrophages, neutrophils, monocytes, T cells, B cells and natural killer cells you would 
need antibodies for the surface markers for each cell population, including CD45 (total 
immune cells), CD11b (monocytes, macrophages), Ly6G (neutrophils), F4/80 
(macrophages), CD3 (T cells), CD19 (B cells), and NK1.1 (natural killer cells). The flow 
cytometer, however, does not have the capabilities to analyze all seven antibodies. To 
overcome this, you can split the sample in half and run either a lymphocyte panel or 
myeloid panel. Each panel would incorporate a dump gate, where all markers for the other 
cell types would be added with the same fluorochrome label. For example, all myeloid or 
lymphocyte lineage markers would be stained with one color and the other lineage markers 
would be stained with individual fluorochromes.  
The concentration of each antibody and the recommended amount to use for staining 
is usually found on the supplier’s website. Most of our flow cytometry antibodies are 
purchased from Biolegend. For example, CD45-FITC comes at a 0.5 mg/ml concentration 
and is recommended to use less than or equal to 0.25 µg per 106 cells. Use these values to 
back calculate the volume of antibody that needs to be added to stain each sample. 
However, it is suggested that you titrate the antibody to determine the concentration that 
provides the largest difference in stained and unstained sample. In my experience, using 
half of the recommended antibody will be appropriate for staining.  
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There are specific controls that must be incorporated into your flow cytometry 
experimental design in addition to the samples that will receive the master mix (i.e. the 
staining cocktail). To remove any emission spectra overlap between different 
fluorochromes, single fluorochrome compensation controls must be included. These 
controls are developed when you stain either a small portion of your sample or beads with 
each fluorescently labeled marker individually.  The main thing to consider here is that 
whatever you stain must be as fluorescently bright as your mastermix stained samples in 
order to compensate appropriately. Additionally, you will also need an unstained sample 
to use for compensation. These blank samples will also help you determine where your 
negative populations are as well as determine the level of potential autofluorescence. 
Finally, the use of fluorescent minus one control samples will aid in determining the 
appropriate gating scheme. To develop these controls, you will stain a small portion of your 
sample with a mastermix including all fluorescently labeled markers except for one which 
will be the isotype control of that particular antibody labeled with the same fluorochrome 
as the marker you are using in the mastermix. You will have as many isotype control 
labeled samples as the number of markers in your panel design. The isotype control 
information for each antibody is also found on the supplier’s website.  
B.2 Preparing samples for staining 
 The main type of cells that we have analyzed via flow cytometry have been isolated 
from whole blood, tissues, or cell cultures. Whole blood and cells collected from cultures 
do not need any additional processing prior to staining; however, tissues must be digested 
prior to staining. To digest tissues, inject Liberase, which is a combination of collagenase 
1 and collagenase II, directly into the tissue. The tissue should become clearer as you inject 
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indicating that the cells are being removed from the tissue. Then mince the tissue into tiny 
pieces and incubate in the oven for 20 minutes to activate the liberase. The addition of 
EDTA will stop the reaction for the samples to then be strained through a 100 µm filter to 
remove any undissociated pieces. Cells can then be collected, washed via centrifugation, 
and transferred to polypropylene flow tubes for subsequent staining. All samples should be 
kept in ice until analyzing on the flow cytometer unless otherwise stated. If the tissue is a 
highly vascularized tissue such as the liver, the red blood cells also need lysed using ACK 
buffer. If multiple people are dissociating samples from the same experiment, be sure to 
keep track of who prepared which samples in case there is any variability. Additionally, a 
small experiment was conducted in 2017 that aimed to compare adipose tissue dissociation 
using liberase or collagenase 1 and the results indicated that the number of total immune 
cells was not significantly different in tissues isolated using either digestion method. 
However, I suggest that this experiment be repeated if this question still remains because 
the variability using collagenase 1 was high.  
B.3 Staining samples  
 Various immune cell populations including macrophages, monocytes, B cells, and 
granulocytes express FC receptors, CD16 and CD32, on their surface. In order to prevent 
non-specific binding to these FC receptors, cells are first incubated with anti-mouse 
CD16/32 antibody that is not fluorescently labeled. Samples are then incubated with the 
appropriate antibody cocktail as determined during your panel design. From this point on 
be sure to keep stained samples in the dark to prevent photobleaching. The unbound 
antibodies are then removed via centrifugation.  Fixing the tissues using fixation buffer 
purchased from Biolegend will allow for the samples to be kept overnight if you aren’t able 
 
135 
to analyze the samples on the flow cytometer until the next day. If they are kept in the dark 
at 4°C, I suggest analyzing them on the flow cytometer within 24-48 hours maximum. If 
the sample is whole blood, the red blood cells can be lysed and fixed simultaneously using 
Biolegend’s Lyse/Fix buffer. Samples are then washed thoroughly and transferred to the 
filter cap polystyrene flow cytometry tubes to remove any debris. Lastly, if using counting 
beads to calculate the number of each cell population, the exact volume of the sample to 
be analyzed on the flow cytometer must be recorded. I suggest pipetting the sample into a 
new polypropylene flow cytometry tube to determine the volume. The samples are 
prepared to be analyzed on the flow cytometer. Carefully, transport the samples on ice, 
counting beads, 100 µL pipette and tips to the medical school.  
B.4 Running the samples on the flow cytometer  
The BD FACS Aria II flow cytometer and cell sorter is located at the University of 
South Carolina Medical School and is housed in the Instrument Resource Facility. Kia 
Zellers is the point of contact for any questions that you may have regarding the machine 
and is responsible for flow cytometer maintenance, such as refilling the sheath fluid or 
emptying the waste.  You will need to contact her for proper flow cytometer training that 
will then allow you to independently use the machine. Like all IRF equipment, the flow 
cytometer must be scheduled prior to use and can be done so on the ILabs solutions website. 
I highly suggest scheduling the flow cytometer for longer than you anticipate.  
Turn the flow cytometer and laser on using the buttons on the left side of the flow 
cytometer. Open the BD FACSDiva software on the computer and begin setting up your 
experiment. Under the “Gower Lab” folder, create a new experiment and label it 
appropriately. Then add a specimen underneath this experiment and label appropriately. 
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You can add multiple “specimens” to the same experiment folder if you are running several 
similar experiments in a short period of time. Then under the specimen, add a sample for 
each sample that you have prepared to run on the flow cytometer and rename each 
appropriately. Next turn the flow stream on by clicking the red X on the top of the stream 
and wait until the drops are even. If these samples have been ran before, then you most 
likely will have a good idea of the fluorochrome settings that should be used and the dot 
plots that need to be created; however, if this is the first time that you are running these 
samples, I suggest making an extra mastermix stained sample to use to determine the 
appropriate fluorochrome settings (under cytometer settings, parameters). Fluorochromes 
fluorescent intensity is on a log scale and forward and side scatter are on a linear scale. 
Knowing which cell populations you are interested in will allow you to initially create dot 
plots and target populations within those dot plots. For example, if you are analyzing the 
number of macrophages within the sample, you know those cells are positive for CD11b 
and F4/80. Therefore, you first make an FSC versus SSC plot and gate out any debris likely 
located at the origin. You can then plot that population on the fluorochromes that CD11b 
and F4/80 are labeled and gate the double positive population. Once you have created the 
dot plots for all the target cells, vortex and then load the extra sample to begin acquisition.   
Additionally, I suggest running this extra sample at a low flowrate (< 3), located on the 
bottom toolbar, in order to have enough time and sample to determine the settings. Once 
acquisition begins, you will see dots collecting on your dot plots, indicating cells. Alter the 
settings to ensure that all of your cells are located and appropriately spread out on the FSC 
versus SSC dot plot and that each fluorochrome positive cells are located at approximately 
103 on the log scale. Be sure to also record forward scatter height and width (FSC-H, FSC-
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W) and side scatter height and width (SSC-H, SSC-W) in order to remove any doublet cell 
populations in the analysis. The other settings that are normally changed are found on the 
bottom toolbar, including number of events shown in your dot plots on the right panel, 
number of events recorded either total or in a particular population, and the flow rate. 
Events are equivalent to the number of cells that have passed through the laser and it is 
good practice to record as many events in your sample as possible. I suggest recording a 
minimum of 5,000 events in each target cell population if possible. I normally select to 
show 1,000,000 so that all of the events will show on the dot plots.  Additionally, I do not 
suggest running the sample at a flow rate higher than 5, as running the samples at a high 
flow rate can increase the variability due to the position of the cells within the laser (i.e. 
more groups and less individual cells). Furthermore, by adding a population statistics table, 
the software will tell you the number of events that are in each population as you run your 
sample.  
Once you have determined your settings and created your dot plots and populations, 
you can start recording your various samples. After loading the sample and the event rate 
is stable (approximately 5 seconds), click record to record your data. If you do not click 
record, your data will not be saved. You have the liberty to analyze any sample in any 
order; however, I suggest starting with your FMO controls to ensure that your gating 
scheme is appropriate and then move on to your mastermix stained samples. If you are 
using counting beads, add the beads prior to vortexing and then load the sample. Counting 
beads are fluorescent in all channels; however, the best gate that I have found for locating 
the counting beads is located on SSC versus APC. Finally, record the blank and 
compensation samples. All samples must be analyzed using the same settings. Collect the 
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data by right clicking the specimen and exporting onto your flash drive. I always save both 
the 2.0 and 3.0 versions just in case; however, I use the 2.0 version during the analysis.  
B.5 Analyzing samples using FlowJo 
 To analyze data using FlowJo, drag and drop files into FlowJo. Because you may 
have a large number of files to analyze, I suggest first organizing the data based on sample 
groupings (i.e. mastermix stained, blanks, compensation controls, and isotype controls) by 
clicking Create New Groups of Samples and dragging and dropping the files into the 
appropriate groups. Then using your compensation samples, gate on your positive and 
negative populations for the fluorochrome used to stain that sample. Ensure that your 
positive populations are as bright in each channel as your sample. If they aren’t, you will 
need to repeat the compensation controls using a different sample with the same settings 
that was used to analyze the main sample. To develop a compensation matrix that can then 
be applied to the rest of your samples, click Platform, Compensate Samples, then Define 
New Matrix. Drag and drop your positive and negative gates for the appropriate 
fluorochrome into the table and then click Compute & Close. To apply the compensation 
matrix to the rest of your samples, select all samples then Platform, Compensate Samples, 
and the title of your compensation matrix. You should see a colored bar to the left of each 
sample denoting that it was compensated.  
Next, use your isotype controls to develop the appropriate positive gates that you will 
then apply to your mastermix stained samples. Use forward scatter vs side scatter plot to 
determine the main cell population as there maybe cell debris located at the origin that 
should be gated out. Then gate out doublets by gating side scatter width versus side scatter 
height. Looking back at our macrophage panel example, one isotype control will be stained 
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with the isotype control for CD45, CD11b, or F4/80. Use the sample stained with the CD45 
isotype control to determine where the positive gate for CD45 should be located. Complete 
this analysis for the samples stained with the CD11b or F4/80 isotype control as well. Then 
copy and paste the gating scheme developed using the isotype controls onto the mastermix 
stained samples.  
 There are different methods of reporting flow cytometry data that are commonly 
used. Dot plots are a convenient way to illustrate significant and obvious differences 
between groups. An easy way to compare dot plots between groups is to use the layout 
function to compare representative samples from each group side by side. Histograms are 
also a common method to depict how mean fluorescent intensities shift between groups. 
The layout function will also allow you to overlay histograms from different samples so 
that they can be compared on a single plot. Furthermore, the number of cells in each cell 
population can be used along with the counting bead concentration and sample volume to 
calculate the number of total cells in each population in the total sample. This cellular 
quantification allows for statistical analysis between groups. Finally, the average mean 
fluorescent intensity of each sample can be determined using the statistic function and can 
then be averaged and statistically compared between groups. This is particularly useful 
when investigating the presence of a marker on a particular cell type.  
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MANUSCRIPT COPYRIGHTS 
 
 
 
 
 
 
 
 
 
 
Figure C.1: Screenshot of permission from ACS Journals to reuse published work 
in this dissertation.  
